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 The recent emergence of West Nile virus (WNV) in the western 
hemisphere has been marked by an increase in severe neurological disease.  
The factors that contribute to this increase in pathogenicity are poorly 
understood, however, there is evidence that the host antiviral response plays a 
significant role in controlling WNV mediated disease.  The innate antiviral 
response is mediated by a variety of pathogen recognition receptors, including 
RIG-I.  Here, we analyzed the RIG-I mediated antiviral response to WNV 
infection. We identified multiple regions of the pathogenic WNV-NY genome and 
antigenome that act as pathogen associated molecular patterns (PAMPs) 
capable of stimulating the RIG-I response.  Additionally, preliminary examination 
of the related, non-pathogenic WNV-MAD78 genome has revealed stimulatory 
regions that differ from those found in the WNV-NY genome.  One of PAMP 
	  
	  
region, the 5’UTR, was analyzed further to elucidate the secondary structural 
elements present in the RNA, which may be contributing to the antiviral 
response.  Similar, equally stimulatory structures were found in the 5’UTR of both 
the WNV-NY strain WNV-MAD78, indicating similar structures may be 
recognized for RIG-I activation.  We also examined the role of DDX3, a DExD/H 
box helicase similar to RIG-I, in WNV infection.  DDX3 appeared to co-localize 
with WNV protein and DDX3 expression was reduced at late points in infection, 
but DDX3 overexpression had no effect on viral replication or protein expression.  
Therefore, the exact role that DDX3 plays during the course of WNV infection 
remains unresolved.  Taken together, our data suggests a specific structural 
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Chapter 1 – Introduction 
 
West Nile virus 
 The expansion of travel into new areas of the world and the subsequent 
increase in contact with members of the global community has meant that a 
growing number of pathogens, especially viruses, have emerged as threats to 
public health in the past few decades.  One such virus, West Nile virus (WNV), is 
a pathogen that has only recently spread into the Western hemisphere, having 
been introduced to the United States in 1999 (111).  WNV has been isolated 
throughout the continental United States as well as parts of Mexico, the 
Caribbean, and Canada. 
West Nile virus biology 
WNV is a positive sense, RNA virus belonging to the family Flaviviridae.  
This family contains a number of viruses, including hepatitis C virus (HCV), 
Japanese encephalitis virus (JEV), and Dengue virus, all of which contribute to 
significant morbidity and mortality worldwide and are therefore widely studied 
(98).   WNV has been endemic to the Middle East and parts of Africa and 
Southeast Asia for many years, but the virus has spread in recent years to the 
United States, where it was first reported in New York (111, 137).  The 
introduction of WNV to new areas of the world has increased the incidence of 
human infection.   The traditional transmission cycle of the virus is from a 
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mosquito vector to birds, the natural host, with humans, horses and several other 
species serving as incidental, dead-end hosts (98, 174).  The disease is 
generally asymptomatic in humans, or results in mild, flu-like symptoms with low-
grade fever, referred to a “West Nile fever.”  In areas where WNV has been 
endemic, approximately 1% of cases present with severe symptoms, including 
high fever, paralysis, and encephalitis.  Infection can even result in death in 
between 3-15% of these severe cases (67, 83, 111).  In contrast, the outbreak in 
the western hemisphere is associated with a higher incidence of severe 
neurological disease, with an average of 30-50% of reported cases within the last 
decade in the United States being associated with neurological symptoms.  WNV 
is now considered the leading cause of domestically-acquired arboviral disease 
and represents a serious public health risk (information found on the CDC 
website www.cdc.gov/ncidod/dvbid/westnile.idex.htm).  Despite the increase in 
both case number and incidence of severe infection, the factors that contribute to 
pathogenicity and severe neurological symptoms in recently emerged strains are 
poorly understood.  
The structure of the viral genome 
The WNV genome is approximately 11 kb in length and encodes ten 
proteins: three structural proteins and seven non-structural proteins.  The 
genome is translated as a single polyprotein and subsequently cleaved by both 
viral and host cell proteases to generate the individual proteins. The virus also 
contains two untranslated regions (UTRs) at the 5’ and 3’ ends of the genome 
(Figure 1).  The virus is capped with a type 1 m7GPPPAmpN2 cap, but lacks a 
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poly-A tail (8, 11, 35,13).  The 3’ UTR also contains a secondary structure that 
results in the production of a single subgenomic RNA (sfRNA), which is common 
to all of the arthropod-borne flaviviruses (55, 164, 170). 
Structure and Function of UTRs 
The 5’ and 3’ UTRs of WNV are predicted to be highly structured regions 
and numerous studies have demonstrated they are required for both replication 
and translation of the viral genome (32, 54, 95, 103, 126).  Despite the apparent 
importance of these structures, their secondary structures have not been 
confirmed by experimental structure probing.  The 5’UTR is composed of the first 
96 to 97 nucleotides (nt) of the genome, depending on strain, and is highly 
conserved between flaviviradae members (22, 98).  There are two predicted 
structures present in the 5’UTR, identified as stem loops (SL) A and SLB (23, 95, 
171).  SLA consists of the first 70nt of the genome and similar SL structures in 
this position are found in most of the flaviviruses.  SLB contains the 5’ initiation 
element known as the upstream AUG region (UAR).  The UAR base pairs with a 
complementary region in the 3’UTR to facilitate viral replication. Additionally, 
interactions between conserved sequence (CS) elements found within the core 
gene and the 3’UTR allow for cyclization of the genome, an important step in the 
synthesis of the minus strand RNA (11, 24, 54, 213).  The 3’UTR also contain a 
SL structure responsible for the production of the sfRNA.  The exact function of 
this sfRNA is unknown.  However, recent studies indicate that it may play a role 
in disrupting the immune response, and mutation of the genome to abolish the 
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formation of this fragment resulted in reduced lethality in mice, suggesting that 
the sfRNA contributes to pathogenicity (94, 105, 108).  
 
Figure 1: A schematic representation of the WNV genome.   
 
Function of the WNV structural proteins  
The first three genes of the viral genome, core (also referred to as capsid), 
pre-membrane/membrane (prM/M) and envelope (E), encode the structural 
proteins involved in viral particle formation.  The virion is ~50 nM in diameter and 
is composed of an icosahedral protein shell composed of the E and M proteins 
incorporated into the viral envelope (22, 98).  The outer surface of the virion is 
smooth, and contains 90 E dimers and 180 copies of M.  The interior of the virion 
contains the nucleocapsid, which is comprised of core protein and viral genome.  
The E protein is a class-2 fusion protein and each monomer contains three 
domains.  Upon acidification due to exposure to the low pH of the endosome, the 
dimers dissociate and rearrange into a trimeric arrangement, allowing for fusion 
with the endocytic membrane (49, 88, 118, 173, 215). The viral RNA and 
nucleocapsid then dissociate and translation of the genome can begin.  The 
nucleocapsid is formed by dimers of Core.  The proteins fold into a confirmation 
whereby positively charged residues cluster on the surface that interacts with the 
1 2a 2b 3 4a 4b 5Cap
Structural      Non-strucutral
5’ UTR 3’ UTR
C prM E 
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RNA while the outer surface is composed of primarily hydrophobic residues.  The 
core protein associates with cellular membranes during entry and egress, and 
therefore contains an internal hydrophobic region flanked by charged residues on 
the C and N terminus.  The C terminal end of the protein also contains an anchor 
region, referred to as core anchor (CA).  The CA acts as a signal peptide for 
translocation of the prM protein into the endoplasmic reticulum (ER) (98).  The 
prM protein serves as a chaperone for proper folding of the E protein (88, 98, 
214, 215).  In its immature form, prM also prevents premature fusion during 
egress from the cell, as the pr portion of the protein covers the fusion peptide of 
E.  PrM is cleaved by the host protease furin to form the M protein in the trans 
Golgi network during maturation, although cleavage is not always completely 
efficient and therefore prM can be found on the virion surface.   
Functions of the WNV nonstructural proteins 
The remaining seven genes of the viral genome encode the nonstructural 
(NS) proteins, identified as NS1, 2a, 2b, 3, 4a, 4b, and 5 (Figure 1).  These 
proteins are involved in viral RNA replication, rearrangement of cellular 
membranes, evasion of the immune response and assembly of the virion (22).  
Most of the nonstructural proteins have been shown to co-localize within the 
replication complex, although in the case of NS1, NS2a, NS4a and NS4b, their 
exact roles within this complex remain to be defined.   
NS1 is a glycoprotein with proposed roles in viral replication and as a 
pathogenicity factor. NS1 co-localizes with the double stranded replicative 
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intermediary form of the genome within replication complexes (200) .  There has 
been some evidence to suggest that this association plays a role in the switch 
from viral replication to translation and that it acts to translocate the polyprotein 
during virion assembly (97, 130).  NS1 can be secreted as a homodimer that 
associates with cellular membranes or as a soluble monomer or hexamer 
composed of three homodimers (2). Both the dimeric and monomeric form of the 
secreted NS1 protein can interact with glycoprotein factor H, an activator of the 
complement cascade, giving it a role in suppression of the host immune 
response (7, 8).  In addition, the production of a frameshift alternative product, 
NS1’, can increase neuroinvasiveness in mice (114). 
NS2a, NS2b, NS4a and NS4b are all small, hydrophobic proteins with a 
variety of functions, although they are not fully characterized (22). Evidence 
suggests that NS2a is involved in the membrane rearrangement required for 
production of virus packets (VPs) and in virion assembly (101, 107, 124).  It has 
also been shown to interfere with the antiviral response through interactions with 
the Janus kinase (Jak) protein, a critical kinase involved in the signaling cascade 
induced by IFN (102).   
NS2b serves as a cofactor for the viral serine protease, NS3 (48, 50).  
Little is known about how the protein functions in it’s role as a cofactor, but 
crystal structure analysis of NS3 with and without the NS2b protein reveals that 
NS3 undergoes substantial structural rearrangement in the presence of NS2b.  
NS3 is a bi-functional protein, the function of which is dependent on the 
conformation adopted in relation to its cofactor proteins (60, 168, 169).  The N-
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terminal end of the protein contains the serine protease domain responsible for 
cleaving the polyprotein into the individual proteins.  In order to be proteolyticaly 
active, NS2b must interact with NS3 to complete the active site of the protein.  
This conformation also provides a platform for the protease specificity site.  The 
C-terminal region of the protein contains motifs that are homologous to an RNA 
helicase, NTPase and RTPase, suggesting a role in RNA replication.  NS4a has 
been identified as the cofactor necessary for the helicase/ATPase activity of NS3 
when it is in its alternate conformation. Indeed, initial studies demonstrated NS4a 
is required for replication as well as membrane rearrangement (3, 107, 149).  
The last small, hydrophobic protein is NS4b.  In addition to a suggested role in 
replication, NS4b has been shown to block the IFN response, although the 
mechanism of disruption is not fully understood (119, 196, 199, 210).   
The final protein is NS5 and is the best characterized of the NS proteins.  
Like NS3, NS5 is a bi-functional protein; the N-terminal end encodes the methyl 
transferase, which is required for capping of the genome, while the C-terminal 
end encodes the viral RNA dependent RNA polymerase.  NS5 has also been 
shown to play a role in blocking the antiviral response by inhibiting the 
phosphorylation of or contributing to the degradation of proteins involved in the 
signaling cascade induced by IFN, thereby preventing the production of antiviral 





Strains and genetic diversity 
One method for determining viral factors that influence pathogenicity is to 
analyze related strains of the virus that produce different disease outcomes.  
WNV has been divided into two primary lineages (92).  The pathogenicity of the 
virus varies depending on the strain and is not lineage specific.  WNV-NY, a 
lineage 1 strain, is a neuropathogenic virus that was isolated in the western 
hemisphere in 2000 from a crow.  WNV-Madagascar (WNV-MAD78) is a lineage 
2, non-neuropathogenic strain isolated in 1978 from a Greater Vassa Parrott.  
When injected directly into the brain of mice, both viruses are neurovirulent; 
however, WNV-MAD78 is considered to be non-neurovinvasive, as injection at a 
peripheral site does not result in neurological disease (92).   Therefore, these 
strains make an excellent model system to define WNV virulence factors.  The 
genomes are only 75% conserved at the nucleotide level.  Direct sequence 
alignment does not reveal any specific region in which changes are clustered, 
although one primary difference that is readily apparent between these two 
strains is in their glycosylation sites.  WNV-NY is glycosylated on both the E and 
prM protein, whereas WNV-MAD78 is glycosylated only on the prM protein. (16, 
66, 127).  Glycosylation of the E protein results in a more neurovinvasive virus in 
mice, increasing virion assembly in cells and viral infectivity (14, 66).  The 3’UTR 
of WNV-MAD78 is also shorter than that of WNV-NY, potentially affecting viral 
replication, production or structure of the sfRNA, or recognition of the virus by the 
host.  These differences may contribute to the variances in pathogenicity 
between these strains.  Another possible explanation for the reduced 
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pathogenicity seen with WNV-MAD78 may lie in the host response. A differential 
innate immune response by the host to WNV-NY verses WNV-MAD78 may 
account for the difference in pathogenicity between the strains 
The viral life cycle 
  Viral entry into the host cell begins with binding of the virus via a host-cell 
surface receptor.  Several potential receptors have been proposed, including 
CD14, GRP78/BiP and αvβ3 integrin, and there is some evidence that different 
receptors are used in a cell-type specific manner (31, 35, 122).  Binding can be 
enhanced by interaction with the attachment factor DC-SIGN/R (42).  Following 
attachment, the virus is taken up by the cell through receptor-mediated 
endocytosis, possibly via clathrin-coated pits (34).  The viral particle is uncoated 
and then released into the host cell cytoplasm.  The positive sense genome is 
translated by host cell ribosomes into a single polyprotein, which is cleaved into 
the individual mature viral proteins by both cellular and viral proteases. The 
production of WNV proteins induces membrane reorganization within the cell, 
including the proliferation of ER membranes, resulting in the formation of VPs, 
randomly folded convoluted membranes (CM) adjacent to the ER, and highly 
structured paracrystalline arrays (PA) (71, 124, 200).  The double-membrane 
VPs produced during membrane rearrangements provide a platform for viral 
genome replication.  Protein translation and proteolytic cleavage are believed to 
take place within the CM and PA structures.  Minus sense RNA (also referred to 
as antigenome or antigenomic RNA) is then produced by the viral polymerase, 
and can in turn serve as a template for further replication of positive sense 
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strands.  Production of antigenomic RNA is asymmetric, with an approximate 
1:10 ratio of antigenomic to genomic RNA being produced (197).  When sufficient 
levels of the structural proteins and genome have accumulated, viral particle 
assembly takes place on the surface of the rough ER.  Virus particles exit the cell 
by moving through the host secretory pathway and are released at the cell 
surface (Figure 2).  
 

















The innate antiviral response    
The ability of a host to detect and respond to invading pathogens is crucial 
in controlling infection.  The host cell innate immune response serves as the first 
level of control against viral pathogens.  The innate antiviral response results in 
the production of cytokines and chemokines that function to limit viral spread.  
This response has multiple consequences, including stimulating the adaptive 
immune response to target infected cells for destruction, and the induction of an 
antiviral state within infected cells.  The innate immune response is mediated by 
a variety of pathogen recognition receptors (PRRs), including the Toll-like 
receptors (TLRs), the RIG-I-like receptors (RLRs), and the Nod-like receptors 
(NLRs).  These PRRs are able to recognize pathogen associated molecular 
patterns (PAMPs) in order to initiate an antiviral response.  Several other proteins 
have also been implicated as PRRs, including the cytoplasmic DExD/H box 
helicase DDX3, although this is not their primary function (162). Binding of 
PAMPs to these receptors results in the activation of signaling cascades.   
Activation of these signaling cascades results in subsequent activation of 
transcription factors capable of inducing the expression of a number of antiviral 
effector proteins, as well as cytokines such as type I IFN.  IFN production in 
particular is an important step in establishing immunity, as this molecule is able 
to stimulate responses linking innate immunity to adaptive immunity, further 





The TLR family is comprised of a number of proteins, with 13 reported 
members, of which 10 are found in humans (6).  They are numbered 1 through 
13, and those responsible for recognition of viral PAMPs are TLR-3, -7/-8, and -9.  
These TLRs are able to recognize double stranded (ds) RNA, single stranded 
(ss) RNA and DNA, respectively, within the endosomal compartment and on the 
surface of cells.  There has also been some recent evidence to suggest that 
TLR-2 and -4 can serve as antiviral PRRs, as they are capable of recognizing 
viral proteins (17, 26, 38, 89, 145, 179).  During the course of West Nile virus 
infection, viral RNA has been shown to activate the antiviral response through 
both TLR-3 and TLR-7. 
All members of the TLR family contain a Toll-IL-1 receptor (TIR), which 
serves as a signaling domain.  However, the TLRs signal via one of two distinct 
pathways (Figure 3).  Upon binding to their cognate ligands, TLR-7/8 recruits 
Myd88, an adaptor protein utilized by several of the TLRs.  Myd88 engages the 
interleukin 1R-associated kinase (IRAK) complex, consisting of several IRAK 
proteins.  These IRAKs in turn phosphorylate TNF receptor-associated factor 6 
(TRAF6). Phosphorylation of TRAF6 can result in the activation of a number of 
transcription factors including nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) and activator protein (AP-1).  NFκB is activated when 
phosphorylation of the inhibitor IκBα results in its degradation.  Removal of IκBα 
reveals a nuclear localization signal on NFκB, allowing free NFκB to translocate 
into the nucleus.  AP-1 phosphorylation is mediated by the activation of a series 
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of kinases, including transforming growth factor β-activated kinase 1 (TAK-1) and 
the mitogen activated protein kinases (MAPKs).   
In contrast, TLR-3 recruits Toll-IL-1 receptor domain-containing adaptor 
inducing IFN-β (TRIF). While TRIF activation induces signaling through TRAF6, it 
can also signal through a separate cascade.  It activates the protein kinases tank 
binding kinase 1 (TBK1) and inhibitor of kappaB kinase-ε (Ikkε), forming a dimer 
of the two proteins.  This hetero-dimer then in turn phosphorylates IRF-3, thus 
converting it to a transcriptionally active form. Activated IRF-3 forms a 
homodimer and is preferentially retained in the nucleus.  In concert with several 
other transcription factors, IRF-3 functions to induce the transcription of 
interferon-β (IFN-β) as well as a number of interferon-stimulated genes (ISGs), 
such as ISG-56, also known as IFIT1, and ISG15 (61). 
The RLRs 
The RLRs are cytoplasmic DExD/H box helicases belonging to the 
superfamily 2 helicases (181).  Activation of either RIG-I or MDA5 results in a 
signaling cascade with the eventual activation of transcription factors that induce 
IFN expression (Figure 2).  In contrast to TLRs, the RLR proteins recognize viral 
RNA in the infected-cell cytoplasm.   There are three members of the RLR family:  
Retinoic acid-inducible gene I (RIG-I), melanoma differentiation association gene 




Figure 3: The innate antiviral signaling cascade.  Several PRRs (orange) are able to 
recognize viral PAMPs in the host cell cytoplasm (the RLRs) or endocytic vesicles (the TLRs).  
Activation of these PRR proteins induces signaling cascades that mediate the activation of 
several different kinases (green), which are then able to phosphorylate and activate a number of 
transcription factors (red).  These transcription factors are able to induce the expression of INF, 


































































RIG-I and MDA5 are involved in the recognition of viral RNA and the 
activation of the innate immune response, and both contain two tandem N- 
terminal caspase activation and recruitment domains (CARDs), a helicase 
domain, and a repressor domain (RD) found on the C-terminal end of the protein.  
Together, the helicase domain and RD constitute the C-terminal domain (CTD).  
LGP2 lacks the RNA recognition domain present in RIG-I and MDA5 and 
therefore does not serve as a PRR.  LGP2 contains only the helicase and 
repressor domains.  LGP2 has been shown, however, to regulate RIG-I and to 
mediate CD8+ T-cell expansion in response to infection (178).  Mutation or 
elimination of the CARDs ablates the signaling capacity of RIG-I or MDA5, while 
overexpression of the tandem CARDs alone results in constitutive signaling, 
even in the absence of viral RNA (10).  The RD, which contains the RNA binding 
domain, acts to repress signaling of the CARD by binding to both the CARD and 
helicase domains (39, 151).  The helicase domain contains an ATP-binding 
domain and a helicase domain.  In uninfected cells, the protein is thought to exist 
in a “closed” conformation in which the repressor sterically hinders access to the 
CARD and helicase domains, preventing signaling (Figure 5).  This closed 
conformation is altered in the presence of viral RNA.  RNA binds the RNA 
binding domain of the RD and ATP binds in the helicase domain.  This results in 
a conformation in which the protein is  “opened,” allowing the CARD to interact 
with downstream proteins (Figure 5) (10).  The now accessible CARD domain of 
the activated RLR interacts with the IPS-1, also referred to as MAVS, VISA, and 
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Cardif (70, 81, 116, 165, 204), another CARD containing protein which is 
associated with the outer membrane of the mitochondria. 
 
  
Figure 4: Structure of the RLR family members.  The RLR family is composed of three 
members: RIG-I, MDA5 and LGP2.  All three family members are comprised of a helicase 
domain, which contains an ATP binding domain and a Repressor domain (RD).  RIG-I and MDA5 
also contain two tandem CARDs, which serve as the signaling domain to downstream proteins.   
 
Both RIG-I and MDA5 signal through this protein, and cells lacking a 
functional IPS-1 are unable to stimulate IFN expression through the RLR 
pathway, regardless of the presence of functional RIG-I or MDA5.  Activated IPS-
1 then signals the phosphorylation of many different proteins, including TBK1 and 
Ikkε, which then in turn phosphorylates IRF-3.  IPS-1 can also activate TRAF6 
and subsequently other factors such as NFκB.  The activation of IRF-3, NF NFκB 
results in the subsequent induction of IFNβ expression (69).  The RLR and TLR 
pathways are therefore somewhat redundant, activating the same subset of 




Figure 5: Conformation of the RIG-I protein both with and without a RNA bound.  RIG-I is 
autoinhibited in the absence of an RNA PAMP.  The flexible linker regions between the CARDs 
and Helicase domain and the helicase domain and RD allow for the RD to be folded over onto the 
CARDs, creating a “closed,” inactive conformation.  When RNA binds the RD, the CARDs are 
released and are then free to participate in downstream signaling. 
   
The IFN response 
IFN-β acts in an autocrine or paracrine fashion, inducing the expression of 
effector proteins to promote an antiviral state (175).  IFN-β is able to bind to the 
IFN receptor (IFNAR) and activate the receptor associated kinases Jak-1 and 
Tyrosine kinase-2 (Tyk-2). Jak-1 and Tyk-2 then phosphorylate and activate the 
signal transducers and activators of transcription (STAT) proteins, which are able 
to hetero- or homodimerize. The dimerized STAT proteins bind IRF-9, forming 
the transcription factor ISGF3.  ISGF3 induces the expression of ISGs, including 
IRF-7, by binding to IFN-responsive sequence elements (ISREs) within the 
genome (Figure 6).  In addition to establishing an antiviral state, thereby 
preventing viral infection of new cells, the production of IFN, ISGs, and other 
cytokines help to limit infection through a variety of mechanisms (30, 41, 110, 




















160, 175, 209).   IFN stimulates expression of MHCII to target infected cells for 
killing by adaptive immune cells, as well as promoting apoptosis of infected cells, 
contributing to viral clearance.  Additionally, recent work has demonstrated that 
type I IFNs can stimulate the maturation of dendritic cells, which can further 
enhance the adaptive immune response.    
 
 
Figure 6: The IFNB receptor pathway.  IFN is able to act in a paracrine or autocrine fashion, 
binding to the IFNα/β receptor on the cell surface and activating the kinases JAK and Tyk, which 
phosphorylate STATs 1 and 2.  Activated STATs 1 and 2 form a complex along with IRF-9, the 
ISGF3, which is able to translocate to the nucleus and bind ISRE in the genome to induce 
























IFN production has also been shown to act as a stimulator of antibody 
production.  The varied responses induced by type I-IFN makes its production an 
important bridge between the innate intracellular antiviral response and the 
adaptive immune response 
Viral PAMPs of RIG-I 
Several viruses have been shown to be recognized by either RIG-I, MDA5 
or both (Table 1) (41, 58, 100, 104, 107, 109, 113, 149, 75, 11).  RIG-I 
recognizes RNA viruses with both positive and negative sense genomes.  
Positive sense viruses include human immunodeficiency virus (HIV), flaviviruses 
such as JEV and HCV, and several paramyxoviruses, including Sendai virus, 
Newcastle disease virus, and respiratory syncytial virus (RSV).  Negative sense 
viruses recognized by RIG-I include vesicular stomatitis virus (VSV) and 
influenza A.  MDA5 is activated by picornoviruses, such as encephalomyocarditis 
virus and Theiler’s virus.    RIG-I and MDA5 are both involved in signaling during 
dengue virus and WNV infection, as well as the dsRNA reoviruses.  The wide 
variety of viruses that are recognized by RIG-I and/or MDA5 suggests these 
proteins are capable of recognizing general properties of viral RNA as opposed 
to motifs or sequences specific to individual viruses.  In the case of WNV, RIG-I 
serves as the initial PAMP sensor.  Both RIG-I and MDA5 are ISGs and are 
therefore simulated after IFN expression. MDA5 serves to expand and/or amplify 




Table 1: Viruses recognized by the RLRs 
 
 
It is important that the host is able to distinguish between viral and “self” 
RNAs, thus the viral PAMPs recognized by both RIG-I and MDA5 must be 
uniquely “viral” in structure. Viral genomes can be long, un-capped plus or minus 
sense RNAs.  In addition, regions of dsRNA within the genome can form complex 
secondary and tertiary structures.  Host cellular RNAs are typically capped, short, 
singled stranded RNAs with limited secondary structure.  RIG-I and MDA5 may 
be able to recognize viral verses host RNAs due to these differences.  Analysis 
of viral PAMPs has revealed a variety of features that serve to activate the RLRs 
(Table 2).  It has been shown that dsRNA containing a 5’PPP serves as a potent 
Virus/ligand genome RLR













Newcastle disease virus RIG-I
VSV (-) ssRNA RIG-I
influenza A (-) ssRNA RIG-I




inducer of RIG-I signaling (74, 79, 140, 157, 158).   Blunt-ended, dsRNA is also 
bound by RIG-I, although the affinity is weaker than for RNAs containing the 
triphosphate (94, 112).  MDA5 has been shown to recognize long, dsRNA, at 
least 200nt in length (79).  
Several studies have identified ligands of RIG-I that are virus specific, 
although these features are still structural in nature rather than related to viral 
sequence.   The leader RNA of the measles and rabies viruses has both been 
shown to stimulate RIG-I.  Additionally, a distinct polyU/C region in the 3’UTR of 
several viruses, including HCV, rabies and ebola virus are potent RIG-I 
activators. Products formed by the degradation of HCV RNA by the cellular 
antiviral effector, RNaseL, and panhandle structures found at the end of the 
influenza A genome, particularly those that are blunt ended and also contain a 
5’PPP have also been shown to activate RIG-I (12, 143, 146, 152).  RNAs 
lacking the 5’PPP have been shown to stimulate RIG-I, although this stimulation 
is generally much weaker than seen with RNA that does contain a 5’PPP (105, 
192).  Some non-viral RIG-I ligands include regions of dsRNA formed as result of 










Table 2: Structures capable of stimulating a RIG-I response.  Adapted from Onoguchi, K. et 




While RNAs containing 5’PPP have been identified as PAMPs, the 
experiments used to determine them do not take into consideration that viral 
RNAs are rarely found as “naked” RNA in the cell.  RIG-I recognition of RNA 
containing a free 5’PPP fails account for the fact that some viruses are capped in 
order to mimic the host cell RNA; either stealing host caps or producing a cap-
like structure.  Thus, while RNA containing a 5’PPP is considered the most 
potent RIG-I activator, other PAMP structures are likely similarly stimulatory 
during a native infection. 
Studies identifying viral PAMPs have also found that regions of dsRNA 
formed as the result of secondary and tertiary interactions can also serve as RIG-
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I ligands.  The regions of the HCV, ebola, measles and rabies virus that contain 
identified viral PAMPs are known to be highly structured.  Additionally, several 
studies have found that the presence of a hairpin or panhandle structure at the 5’ 
end of an RNA molecule is a strong stimulator of the RIG-I response (12, 146, 
157, 176).  This suggests that RIG-I recognition is related to a secondary 
structural motif found within these RNAs.  This is not surprising, as RNA readily 
forms complex secondary and tertiary interactions and several secondary 
structures found in viral RNAs have been shown to be indispensible for viral 
replication and are therefore stably maintained within the genome.   
In the case of WNV, the viral genome is capped at the 5’ end and 
therefore lacks a free 5’PPP.  Additionally, WNV RNA is contained within 
membrane structures formed in order to facilitate replication, and therefore would 
not necessarily be accessible.  The virus does not encode a distinct polyU/UC 
region, nor does it synthesize a leader RNA during replication.  This would 
suggest that another factor(s) is being recognized by RIG-I upon initial infection.  
Within the WNV genome, both 5’UTR and 3’UTR are reported to be highly 
structured, and there is also evidence for a strong stem loop structure within the 
viral genome at the junction between NS1 and NS2a (114).  These structural 






RIG-I/RNA binding  
Several studies have detailed the structure of RIG-I bound to a RNA 
ligand (36, 76, 84, 106).  RIG-I bound to a dsRNA 10-mer shows that the CTD 
completely encases the RNA within a binding pocket.  This pocket is lined with 
positively charged residues, which interact with the negatively charged RNA 
backbone to mediate binding.    The bound RNA retains its conformation and 
does not show any signs of de-stabilization or unwinding, despite a reported 
helicase domain within RIG-I.  The 2’-hydroxyl groups of the bound RNA interact 
with amide groups found in the binding cavity of the CTD, and these particular 
interactions explain the finding that modification of the 2’ end of the RNA can 
inhibit RIG-I activation (106).  RIG-I binding to RNA based on charge interactions 
further supports a structural component, such as the 5’PPP, being required for 
recognition by RIG-I, rather than a specific RNA sequence.  Interactions within 
the binding pocket and the 5’PPP of the ligand RNA result in stronger binding 
than RNAs lacking a 5’PPP (76, 84, 87, 106).  However, there is also evidence 
that RNA can bind, albeit more weakly, to the helicase domain of RIG-I.  It is 
proposed that the weaker interaction between this domain and RNA allows RIG-I 
to constantly bind RNAs within the cell to “scan” for potential PAMPs; only upon 
binding an RNA that contains a 5’PPP or other structural element denoting it as 
“non-self” can it undergo the conformational change that allows CARD signaling 
(personal communication, Michael Gale).  The “scanning model” is supported by 
work that demonstrates RIG-I can act as a translocase, moving along the RNA 
without inducing signaling (120). 
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Viral subversion of the antiviral response 
A number of viruses have developed mechanisms to escape or actively 
interfere with the host innate antiviral response.  For example, HCV inhibits the 
innate antiviral response by blocking signaling through the RIG-I pathway. The 
viral protease, NS3/4a cleaves the IPS-1 protein, thereby disrupting the signaling 
cascade and preventing RIG-I induced IFN expression (51, 96).  WNV is able to 
similarly interfere with the innate immune response at later points in infection, 
after viral protein production has begun.  The WNV NS2a, NS4b, and NS5 
proteins have all been shown to interfere with or block IFN signaling and the 
antiviral response.  However, at early points post infection, WNV evades 
detection by the host cell rather than actively impeding the RIG-I signaling 
pathway.   This is evidenced by the fact that the appearance of antiviral effector 
proteins coincides with peak viral titers, between 16 and 24 hours post infections 
(hpi).  This delay is beneficial for WNV, as the virus is able to establish a 
productive infection before the innate antiviral response is induced.  The virus is 
thus able to replicate and spread before the induction of the IFN, as well as allow 
time for the accumulation of proteins that act to shut down antiviral signaling. 
The immune response to WNV 
The factors that contribute to the pathogenicity of WNV are not well 
understood.  One factor may be the strength or kinetics of induction of the innate 
immune response.   It is therefore important to understand the host innate 
intracellular immune response to infection.  Several studies have analyzed the 
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immune responses, both innate and adaptive, to WNV and other flavivirdae 
family members, in an effort to characterize the factors that influence 
pathogenesis.  During the innate response to WNV, TLR-3 and -7, as well as 
RIG-I and MDA5, can serve to induce the expression IFN and initiate an antiviral 
response.  However, the precise role of TLR-3 in WNV infection remains 
controversial.  TLR-3 has been reported as being important for stimulating an 
immune response to WNV. Abrogation TLR-3 resulted in enhanced lethality in 
infected mice (40).  There has also been a report, however, that the knock down 
of TLR-3 increases the resistance to lethal WNV infection in mice (190).  
In contrast to TLR-3, TLR-7 knock down in mice resulted in increased 
neuroinvasion as a result of the failure of macrophages to migrate to the sites of 
infection and prevent the spread of the virus (185).  This suggests that TLR7 
signaling is important for the production of cytokines necessary to attract 
leukocytes critical for viral clearance. Additionally, activation of TLR7 in 
keratinocytes has been shown to result in the migration of Langerhan cells from 
the initial site of infection within the skin into draining lymph nodes (44, 194).  
This is both positive, as these cells then traffic to lymph nodes and attract 
leukocytes, and negative, as this allows WNV to spread to new areas (77).   
Studies analyzing the connection between the innate and adaptive 
immune responses have found that induction of a strong innate immune 
response can often have both positive and negative consequences during 
infection.  While induction of interferon and other cytokines can increase 
trafficking of leukocytes to infected areas (44, 59, 77, 191), it is also thought to 
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increase the permeability of the blood-brain barrier, potentially providing the virus 
access to the brain and increasing neuro-pathogenesis (43, 44, 190).  For 
example, increased production of cytokines activated through TLR-3 signaling in 
older mice resulted in an increase in inflammation in the brain during infection 
with WNV (85).   
  Although RIG-I is known to be an important component of the innate 
antiviral response to WNV, little is known about how the response is induced 
during infection.  Identification of the PAMPs associated with WNV will provide 
important information regarding the ability of RIG-I to identify and respond to 
WNV RNA.  In the present studies, we characterize the regions of the WNV 
genome that are capable of inducing a RIG-I mediated antiviral response.  We 
also analyze the structure of one of these PAMPs in order to further explore the 










Chapter 2- Identification of Multiple RIG-I-Specific 
Pathogen Associated Molecular Patterns Within the 
West Nile Virus Genome and Antigenome 
 
Introduction 
West Nile virus (WNV) is a positive-sense, single-stranded RNA virus from 
the family Flaviviridae.  The genome is ~11kb and consists of an open reading 
frame (ORF) flanked by 5ʹ′ and 3ʹ′ untranslated regions (UTRs).  Within the UTRs, 
conserved sequences and predicted secondary structures encode the signals for 
negative strand synthesis, genome amplification, translation, and packaging.  
The incoming viral genomic RNA functions as a template for both translation, 
which produces a single polyprotein, and replication.  The viral polyprotein is co- 
and post-translationally cleaved by host and viral proteases to generate ten 
individual proteins. The structural proteins, core (C), membrane (prM/M), and 
envelope (E), are involved in viral assembly, host cell binding, and entry.  The 
seven nonstructural (NS) proteins (NS1, NS2A/B, NS3, NS4A/B, and NS5) 
support viral replication and evasion of the host antiviral response.  Following 
polyprotein synthesis, genomic RNA is transcribed by the viral polymerase, NS5, 
to generate the complementary minus-strand antigenome, which serves as a 
template for synthesis of additional genomic RNA.  Newly synthesized genomic 
RNA is either translated by the host cell or packaged into virus particles(21, 22, 
29, 98).  
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In areas where WNV is endemic, such as the Middle East, Africa, and 
Asia, infection is typically asymptomatic or associated with a mild febrile illness 
known as West Nile fever(137).  In contrast, recent outbreaks in the Western 
hemisphere have been marked by an increase in disease severity, including 
meningitis, encephalitis, and acute flaccid paralysis(67, 83, 121).  Since its 
introduction into the United States in 1999, WNV has spread to every state within 
the continental United States, as well as parts of Canada, Mexico and the 
Caribbean (information found on the CDC website 
www.cdc.gov/ncidod/dvbid/westnile/index.htm).  As of January 2012, yearly 
outbreaks of WNV have resulted in 13,229 reported cases with neurological 
complications and 1,263 deaths, making WNV the leading cause of mosquito-
borne neuroinvasive disease in the United States.    
The ability to rapidly sense an invading pathogen and respond 
appropriately is a critical factor influencing the outcome of infection.  The 
intracellular pathogen recognition receptor (PRR) RIG-I plays a critical role in 
sensing a wide variety of viruses, including positive strand viruses such as WNV, 
Japanese encephalitis virus (JEV), hepatitis C virus (HCV), dengue virus and 
poliovirus, and negative strand RNA viruses such as paramyxoviruses, influenza, 
and vesicular stomatitis virus (VSV)(53, 80, 146, 152).  The fact that RIG-I 
detects a wide variety of viruses spanning multiple families suggests that it is 
able to interact with multiple substrates.  Recent evidence indicates that double 
stranded structures within viral RNAs function as primary activators of RIG-I 
during infection (12, 15, 79, 109), though 5′ triphosphate (5′ppp) moieties 
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enhance detection of short dsRNAs (74, 140, 157, 158).  Additionally, poly-U⁄UC 
motifs in the genomes of HCV, measles, rabies and Ebola viruses are important 
for activating RIG-I (152).  Once activated by a viral PAMP, RIG-I initiates a 
signaling cascade that results in the activation of latent transcription factors such 
as interferon regulatory factor 3 (IRF3)(69, 175, 180).  Activation of IRF3 leads to 
the induction of type-I interferons (IFNs) as well as a subset of antiviral effector 
proteins such as IFN-stimulated gene 56 (ISG56) (69, 81, 175, 180). The 
induction of these IRF3 target genes results in the establishment of an antiviral 
state within in the cell, which blocks viral replication.   
As eukaryotes evolved strategies to combat invading pathogens, viruses 
have co-evolved processes to escape them.  While many viruses actively impede 
the RIG-I signaling pathway (9, 20, 56, 99, 113, 134, 135), the pathogenic strain 
of WNV, WNV New York (WNV-NY), eludes detection at early times post-
infection (52).  However, the mechanism(s) by which WNV evades detection 
early during infection is currently unclear.  We have previously demonstrated that 
cells treated with UV-inactivated WNV fail to induce an antiviral response, 
suggesting that RIG-I senses a product of viral replication.  Furthermore, the 
WNV-NY genome lacks a poly-U/UC region, suggesting that RIG-I senses either 
dsRNA structures within the WNV genome or antigenome or an as of yet 
unidentified stimulatory motif.  To distinguish between these possibilities, we 
undertook a systematic analysis of the WNV-NY genome and antigenome to 
define RIG-I-specific PAMPs.  Multiple RIG-I stimulatory regions were identified 
throughout the WNV genome and antigenome.  However, incorporation of these 
	  
31	  
regions into larger RNAs abolished their stimulatory potential, suggesting that the 
WNV PAMPs are masked in the context of the full genome and antigenome.  
This masking of the PAMPs likely accounts for WNV’s ability to evade the innate 
immune response early during infection.   
 
Results 
WNV proteins do not induce an antiviral response. 
Expression of the measles virus nucleocapsid protein alone has been 
shown to be sufficient to induce the host antiviral response (182).  Therefore, we 
assessed the stimulatory capacity of WNV proteins from a pathogenic and 
nonpathogenic strain utilizing a luciferase reporter.  Huh7 cells were transfected 
with a RIG-I-dependent luciferase reporter, ISG56-luc (182), and subsequently 
infected with Sendai Virus (SenV), a potent RIG-I-specific activator of the innate 
immune response, or transfected with plasmids encoding specific WNV genes.   
Cultures transfected in parallel were assessed for protein expression using 
western blot analysis (Table 3).  Luciferase levels in cultures expressing WNV 
proteins were similar to mock transfection controls, suggesting that WNV proteins 






Table 3: Summary of WNV protein expression experiments.  
a) WNV gene. Cell lysates were prepared 8 hr post transfection and b) viral protein expression 
was assessed by western blot analysis +, protein expression, - no protein expression. c) +, 
luciferase levels were above the mock transfected control; -, luciferase levels similar to mock.  
Values represent the average luciferase expression compared to mock (± standard error) from a 
minimum of two independent experiments.  
 
The 5′ and 3′ UTRs of WNV induce an antiviral response.   
Because secondary structures within RNA are essential for recognition by 
and activation of RIG-I (12, 15, 74, 79, 105, 109, 120, 146, 157, 158), we 
hypothesized that the highly structured 5′ and 3′ UTRs of WNV stimulate RIG-I.  
Therefore, we assessed the capacity of these regions to stimulate a RIG-I-
dependent antiviral response using a luciferase reporter assay.  The assay was 
performed as previously described, but transfection with RNAs corresponding to 
the genomic (+) or antigenomic (-) 5′ and 3′ UTRs was used instead of plasmids 
encoding the WNV proteins.  Cell lysates were recovered and analyzed for 
luciferase expression 8 hr after RNA transfection to ensure that the induction of 
luciferase expression was due to the primary activation of the RIG-I signal 
transduction pathway and not subsequent feedback amplification loops.  
WNV-NY Protein Luciferase  WNV-MAD78 Protein Luciferase  
Genea Expressionb Expressionc Genea Expressionb Expressionc 
C + - C + - 
prM + - prM + - 
E + - E + - 
NS1 + - NS1 + - 
NS2a + - NS2a + - 
NS2b + - NS2b + - 
NS3 + - NS3 + - 
NS4a + - NS4a + - 
NS4b + - NS4b + - 
NS5 + - NS5 + - 
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Significant induction of luciferase expression was detected in SenV-infected cells 
as well as cultures transfected with the WNV 5′ (+) and 3′ (-) UTRs (Figure 7A).   
In contrast, neither the WNV 3′ UTR (+) nor WNV 5′ UTR (-) fragments induced 
luciferase expression. In order to more accurately mimic the RNAs present 
during a native infection, the stimulatory capacity of the 5′ UTR (+) containing a 
cap structure and the 5′ UTR (-) containing a 5′ PPP were also examined (Figure 
7A).  Neither the presence of a capped structure on the 5′ UTR (+) nor a 5′ PPP 
on the 5′ UTR (-) altered the stimulatory capacity of these fragments.  
The robust induction of the antiviral response by the capped 5′ UTR (+) 
fragment suggested that the incoming viral genome is capable of functioning as a 
PAMP for RIG-I detection.  However, the failure of WNV to initiate a rapid 
antiviral response indicates that this region is not accessible to RIG-I early in 
infection (52).  Interactions between the 5′ and 3′ ends of the WNV genome have 
been shown to be essential for genome replication, suggesting that the 5′ UTR 
does not function as an independent structural element during infection.  
Therefore, we generated a construct consisting of the 5′ UTR to the conserved 
sequences (CS) element, located in the N- terminal coding region of the C gene, 
linked to the 3′ UTR by the egfp reporter gene (5′UTR+CS-eGFP-3′UTR).  
Neither CIP-treated nor capped 5′UTR+CS-eGFP-3′UTR RNAs stimulated 
luciferase expression (Figure 7B), suggesting that the 5′ UTR is not a functional 





Figure 7: The 5′ UTR (+) and 3′ UTR (-) region of the WNV-NY genome induce an antiviral 
response.  Huh7 monolayers were transfected with pISG56-luc and pCMV-Renilla 16 hr prior to 
infection with SenV or transfection with 500 ng of the indicated RNAs in triplicate.  Cell lysates 
were prepared 8 hr post transfection and assayed for luciferase activity.  Values represent the 
average luciferase expression compared to mock (± standard error) from a minimum of two 
independent experiments.  Statistical analysis was performed using Dunnett’s multiple 
comparison analysis, * p<0.05, ** p<0.01 *** p<0.001. (A) Cells were transfected with RNA 
fragments corresponding to the genomic or antigenomic 5′ and 3′ UTRs.  (B) Cells were 
transfected with 5′UTR+CS-eGFP-3′UTR RNAs.  
  
Multiple regions of the WNV genome and antigenome induce the 
host antiviral response.   
To determine whether other regions of the genome also harbor RIG-I 
PAMPs, the stimulatory capacity of RNAs corresponding to the individual WNV 
genes was assessed.  While several fragments induced low to moderate levels of 
luciferase expression, only RNAs corresponding to NS2a (+), E (-), NS2a (-) and 
NS4a (-) functioned as potent stimulators of the antiviral response (Figure 8A & 
B).  Thus, multiple regions within the WNV genome and antigenome are capable 
of stimulating an antiviral response.  
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3’UTR(  ) 
3’UTR(+) 
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Figure 8: Multiple regions of the WNV genome and antigenome induce an antiviral 
response.  Cells were transfected with ISG56-luc and pCMV-Renilla as described in Figure 7.  
Cultures were subsequently transfected with 500 ng of RNA fragments corresponding to genomic 
(A) or antigenome (B) orientation of WNV genes.  Luciferase expression was assessed as 
described in Figure 7. 
 
The antiviral response to WNV PAMPs is RIG-I-dependent.   
The rapid and robust induction of luciferase expression by the 5′ UTR (+), 
3′ UTR (-), NS2a (+), E (-), NS2a (-) and NS4a (-) RNAs was indicative of a RIG-
I-dependent response.  To confirm the specificity of this response, the ability of 
the identified PAMPs to form a stable complex with RIG-I was examined using 
limited trypsin digestion.  This assay assesses the ability of a PAMP to induce 
conformational changes in RIG-I associated with the generation of the signaling-
active form s(151, 152, 180).  Incubation of E.coli-purified RIG-I with each of the 
WNV PAMPs identified above resulted in the accumulation of a 17-kDa trypsin 
resistant band indicative of the signaling-active from of RIG-I (Figure 9A).  
However, only a weak band was detected in the presence of the 5′ UTR (+) 
fragment, suggesting that, unlike the other PAMPS, this fragment does not bind 
Nonstructural Structural 













































































tightly to RIG-I.  We further verified the specificity of the identified PAMPs using 
the RIG-I-deficient Huh7.5 cell line (Figure 9B) (19, 177).  High levels of 
luciferase expression were detected in control cells transfected with a 
constitutively active form of RIG-I, N-RIG.  In contrast, WNV RNA fragments did 
not induce an antiviral response in the absence of functional RIG-I.  Together, 
these findings indicated that the WNV PAMPs identified above induce a RIG-I-
dependent antiviral response. 
 
 
Figure 9: WNV PAMPs induce a RIG-I-specific antiviral response.  (A) Purified RIG-I was 
incubated with control dsRNA or the indicated WNV RNA fragments prior to the addition of 
trypsin.  Digestion products were separated on a 12.5% SDS polyacrylamide gel and visualized 
by Coomassie stain.  (B) Huh7.5 monolayers were transfected with luciferase reporter constructs 
and 500 ng of the indicated RNAs or pEF-flagN-RIG, as described in Figure 7.  Luciferase 


















































































Incorporation of WNV PAMPs into larger RNAs masks their 
stimulatory capacity.  
To determine whether WNV RNA sequences or structures spanning the 
individual genes are capable of stimulating RIG-I, we also tested the stimulatory 
capacity of overlapping segments of the viral genome and antigenome (Figure 
10A & B).  With the exception of the 5′ UTR-prM (+) fragment, the overlapping 
segments failed to induce high levels of luciferase expression, despite the fact 
that several segments contained the highly stimulatory NS2a (+), E (-), NS2a (-) 
or NS4a (-) regions.  
Figure 10: Larger RNAs containing WNV PAMPs fail to activate an antiviral response. Huh7 
monolayers were transfected with ISG56-luc and pCMV-Renilla as described in Figure 7 and 
subsequently transfected with 500 ng of RNA fragments corresponding to the indicated sections 






















































































In this experiment, we transfected cells with equivalent amounts of each of the 
RNAs based on mass.  To ensure that the lack of stimulation by the larger 
fragments was not due to differences in the RNA copy number introduced into 
the cell, we also assessed the stimulatory capacity of these regions by 
transfecting equivalent moles of the various fragments.  While similar levels of 
inductions were detected for the NS2a (+), E (-), NS2a (-) and NS4a (-) regions 
under these conditions, equal molar amounts of the larger RNA fragments did not 
induce luciferase expression (Figure 11).  This suggests that RIG-I is unable to 
efficiently detect WNV PAMPs in the context of a larger RNA even when 
equivalent RNA copy numbers are introduced into the cell.   
 
 
Figure 11:  Larger RNAs containing WNV PAMPs fail to activate an antiviral response even 
with equivalent masses of RNA. Huh7 monolayers were transfected with ISG56-luc and pCMV-
Renilla as described in Figure 7 and subsequently transfected with equal molar amounts (2pmol) 




































































WNV genomic RNAs do not induce RIG-I activation.   
The lack of RIG-I activation by the 5′UTR+CS-eGFP-3′UTR RNAs and the 
larger overlapping segments of the viral genome suggested that the stimulatory 
capacity of these PAMPs is masked in the context of full-length viral RNAs.  
Therefore, we assessed the stimulatory capacity of full-length genomic RNA 
isolated from culture supernatants (FL-WNV) or produced through in vitro 
transcription and capping (capped-FL-IT-WNV) (Figure 12).  Both forms of 
genomic RNA failed to induce luciferase expression, further supporting the 
hypothesis that WNV PAMPs are masked in the context of the full genome. 
 
 
Figure 12: WNV genomic RNAs do not induce an antiviral response. Cells were transfected 
with ISG56-luc and pCMV-Renilla as described in Figure 7.  Cultures were subsequently 
transfected with 500 ng of: (A) genomic RNA isolated from culture supernatants (FL-WNV), (B) 
full length in vitro transcribed and capped WNV genomic RNA (capped-FL-IT-WNV).  Luciferase 





































Processing by the host contributes to the production of RIG-I PAMPs 
Our findings suggested that processing of the viral genome and 
antigenome is necessary to expose the identified RIG-I PAMPs.  Alternatively, 
stimulation of the RIG-I pathway may require high levels of RNA expression, 
which was not re-capitulated in our assay system.  To distinguish between these 
two possiblities, we examined the stimulatory capacity of a WNV RNA fragment 
over a longer time course (Figure 13).  Cells were transfected with 5’-prM (+), 
which served as a positive control as it was the only overlapping fragment to 
show stimulation of RIG-I at 8 hours post transfection, or NS4b-2b (-).  As 
previously observed, by 8 hours post transfection, 5’-prM (+) RNA induced 
luciferase expression, while NS4b-2b (-) did not.  However, after 16 hours post 
transfection, both the 5’-prM (+) and NS4b-2b RNAs were able to induce 
luciferase expression, suggesting that cellular processing may be liberating 





Figure 13:  Larger RNA containing WNV PAMPs induce an antiviral response over time. 
Cells were transfected with ISG56-luc and pCMV-Renilla as described in Figure 7.  Cultures were 
subsequently transfected with 500 ng of the indicated RNAs.  Cell lysates were prepared 8, 16 
and 24 hrs post transfection and assayed for luciferase activity.  Values represent the average 
luciferase expression compared to mock (± standard error) from a minimum of two independent 
experiments.  Statistical analysis was performed using Dunnett’s multiple comparison analysis, * 
p<0.05, ** p<0.01 *** p<0.001. 
 
To confirm the activation detected at later time points post transfection 
was RIG-I specific, we assessed the stimulatory capacity of these RNAs over 
time in Huh7.5 cells (Figure 14).  Luciferase expression was not detected at any 
point in cells transfected with NS4b-2b (-) RNA, confirming stimulation by this 
PAMP is RIG-I-dependent.  Abrogation of RIG-I signaling also ablated luciferase 
expression in cells transfected with 5’-prM (+) at 8 hours.  However, significant 
luciferase expression was detected at 24 hours post transfection, suggesting that 










































Figure 14: Stimulation by larger WNV RNAs over time is RIG-I specific. Huh7.5 Cells were 
transfected with ISG56-luc and pCMV-Renilla as described in Figure 7.  Cultures were 
subsequently transfected with 500 ng of the indicated RNAs.  Cell lysates were prepared 8, 16 
and 24 hrs post transfection and assayed for luciferase activity.  Values represent the average 
luciferase expression compared to mock (± standard error) from a minimum of two independent 
experiments.  .  Statistical analysis was performed using Dunnett’s multiple comparison analysis, 
* p<0.05, ** p<0.01 *** p<0.001. 
  
Subgenomic flavivirus RNA does not induce RIG-I activation 
We sought to further define the cellular processing pathways that 
contribute to PAMP production.  During infection, incomplete digestion of 
genomic viral RNA by the 5′-3′ exoribonuclease XRN1 results in the 
accumulation of a highly structured 3′ UTR-derived monophosphorylated 
subgenomic RNA (sfRNA) (24, 55, 141).  To determine if sfRNA can serve as 
PAMP, we tested the stimulatory capacity of both a CIP-treated and a 
monophosphorylated sfRNA construct.  Although luciferase expression in cells 
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consistently higher than background levels, the increase in luciferase expression 
did not reach statistical significance for either RNA (Figure 15).  This finding 
suggests that sfRNA does not function as a major PAMP during WNV infection 
and is consistent with previous reports that the sfRNA promotes WNV 
pathogenesis (141, 159, 164).   
 
Figure 15:  WNV subgenomic RNAs do not induce an antiviral response. Cells were 
transfected with ISG56-luc and pCMV-Renilla as described in Figure 7.  Cultures were 
subsequently transfected with 500 ng of the indicated sfRNA constructs.  Luciferase expression 
was assessed as described in Figure 7. 
	  
Discussion 
 In this study we utilized a systematic approach to identify RIG-I-dependent 
PAMPs present in the WNV genome and antigenome.  Our findings 
demonstrated that WNV, in contrast to many other viruses (143, 152, 157, 188), 
encodes multiple segments located throughout the genome and antigenome that 
are capable of stimulating RIG-I.  The lack of sequence similarity between the 



































regions rather than a specific sequence motif.  Secondary structural predictions 
indicate that the identified stimulatory regions within the WNV genome are highly 
structured (Figure 36-42, see appendix 5). While these structural predictions 
need to be tested experimentally, they provide a conceptual scaffold to begin 
defining the structural elements involved in RIG-I detection.     Our finding also 
suggest that the intact the WNV genome and antigenome are poor activators of 
RIG-I.  Larger RNA fragments as well as the full-length genomic RNA failed to 
induce the rapid activation of the antiviral response. These findings are 
consistent with a recent report demonstrating that RIG-I does not bind to the full-
length genome of SenV (12).   
Multiple factors may play a role in masking WNV PAMPs within full-length 
viral RNAs. It is possible that the secondary structures detected by RIG-I are 
altered or abolished in the context of the full genome.  Alternatively, tertiary 
structures within the viral RNA may sterically hinder RIG-I’s ability to bind the 
PAMPs.  Comparison of the secondary structure predications for the 5’UTR 
alone and the 5’UTR in the context of the viral genome or the 5’UTR-prM 
fragment suggests that the structure of this region is not substantially altered 
when incorporated into larger RNAs (Figure 42).  However, in the case of the 
incoming genome, the stimulatory capacity of the capped 5′ UTR (+) may be 
obstructed by several additional factors.  Upon entering cells, the viral genome 
undergoes cap-dependent translation to generate the viral polyprotein.  Thus, 
host translational machinery may block RIG-I’s access to this region.  The viral 
genomic RNA also serves as a template for synthesis of the negative sense 
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antigenome, which requires interactions between the conserved sequence (CS) 
elements located within the 5′ end of core and the 3′ UTR as well as base pairing 
between a 5′ UAR (upstream initiation AUG region element) and a 3′ UAR.  
Therefore, long distance interactions between the 5′ and 3′ UTRs may sequester 
the stimulatory signals within the 5′ UTR early in infection.  The observations that 
the 5’UTR-prM fragment stimulated RIG-I, while the 5′UTR+CS-eGFP-3′UTR 
fragment did not, is consistent with this hypothesis.   
 Our findings suggested that WNV also evades detection at early times 
post-infection by sequestering potential PAMPS within the viral genome and 
antigenome.  The mechanism(s) by which WNV PAMPs eventually become 
accessible to RIG-I during the course of infection are currently under 
investigation.  As previously demonstrated for SenV and influenza virus, 
subgenomic defective interfering (DI) particles may play a role in stimulating RIG-
I activation (12).  The deletion of large segments from the viral genome may 
result in the exposure of WNV PAMPs that were previously buried within the full-
length viral RNAs, thus providing the proper context for RIG-I recognition.  In 
addition, the normal cellular processes of RNA degradation may be involved in 
the exposing of WNV PAMPs within the genome during the course of infection.  
This hypothesis is supported by the observation that when larger fragments of 
the WNV genome, which failed to induce a RIG-I response by 8 hours, are 
transfected into cells, RIG-I stimulation is observed 16 and 24 hours post 
transfection.  The fact that the subgenomic sfRNA of WNV failed to substantially 
activate RIG-I suggested that the exonuclease XRN1 is not involved in liberating 
	  
46	  
RIG-I PAMPs.  However, other cellular pathways, such as the “no-go” RNA 
degradation pathway, which is triggered by stalled ribosomal movement, may be 
involved in the processing of WNV viral RNAs (45, 183, 184).  Furthermore, as 
has been demonstrated for HCV, activation of the OAS/RNAseL pathway later in 
infection may liberate additional PAMPs that help sustain and/or amplify the 
antiviral response (109, 156). In the case of the WNV antigenome, alternative 
RNA processing pathways may be required for the release of virally encoded 
PAMPs.  The antigenome of WNV exists within the cell in two forms, the double-
stranded replicative form (ds-RF) and the replicative intermediate (RI).  The ds-
RF consists of a nascent antigenome paired with the genome template, while the 
RI consists of a single copy of the viral antigenome and multiple strands of 
nascent genomic RNA being synthesized (58, 198).  Detection of viral 
antigenome by the host cell may be limited due to the fact that the RI is 
sequestrated within membrane invagination.  However, processing the ds-RF by 
either the cell’s RNAi or ADAR/TSN pathway may liberate PAMPs from the WNV 
antigenome (154, 155, 186).  These mechanisms, as well as other as of yet 
unknown cellular degradation pathways, may contribute, individually or in 
concert, to the liberation of PAMPs.  Further analysis of the WNV RNAs 
produced both in vitro and in vivo will be necessary to more precisely map the 
WNV stimulatory regions with the viral genome and antigenome and to elucidate 




Chapter 3 – Analysis of the WNV 5’UTR 
 
Introduction 
WNV is a (+) sense single stranded RNA virus of the family Flaviviridae.  
The WNV genome is ~11kb in length and encodes ten proteins.  The genome is 
also flanked by 5’ and 3’ untranslated regions (UTRs).  These regions have been 
previously reported to be critical for proper RNA translation and viral replication 
(32, 65, 95, 187, 213).  The 5’UTR is either 96 or 97 nucleotides (nt) in length, 
depending on the strain (92).  Several structure predictions, confirmed through 
mutational analysis, have determined that the 5’UTR is composed of 2 stem loop 
(SL) structures, identified as SLA and SLB.  SLA is comprised of the first 70 
nucleotides of the genome.  SLB is located at the 3’ end of the 5’UTR and 
contains the upstream AUG region (UAR).  The 5’ UAR interacts with a 
corresponding sequence in the 3’UTR and is critical for genome cyclization and 
RNA synthesis.   
WNV has emerged in the past decade as a new public health threat in the 
Western hemisphere. Infection in regions where the virus was previously 
endemic typically results in a mild, febrile illness.  However, strains that have 
recently emerged in the United States show a much higher incidence of severe 
neurological disease symptoms (111, 137).  In the last year alone, there have 
been 5,387 reported cases in 2012, with 2,734 patients suffering severe 
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neurological disease and 234 deaths (Information from the CDC website, www. 
http://www.cdc.gov/ncidod/dvbid/westnile/index.htm).  The factor(s) that 
contribute to the differences in pathogenicity between strains is poorly 
understood, although the induction of the host antiviral response may influence 
WNV pathogenicity. 
The rapid induction of the innate immune response, mediated by pathogen 
recognition receptors (PRRs), is critical to limiting the scope and severity of 
infection.  The cytoplasmic PRR retinoic acid inducible gene I (RIG-I) has been 
shown to be an important mediator of the innate immune response during WNV 
infection (53).  Activated RIG-I is able to initiate a signaling cascade that results 
in the phosphorylation, dimerization and translocation of the transcription factor 
interferon regulatory factor 3 (IRF3) to the nucleus.  IRF3 is able to directly 
induce the expression of several interferon-stimulated genes (ISGs), including 
ISG56 and ISG15 (61, 175).  It also, in concert with other transcription factors, is 
able to induce the expression of interferon β (IFN-β) and thus initiate a type I IFN 
mediated antiviral response (69).  We previously reported that WNV-New York 
(WNV-NY) is able to evade the innate immune response at early times post 
infection (52).  This allows the virus to establish a productive infection and spread 
to neighboring cells prior to the induction of a robust innate antiviral response. 
RIG-I and other PRRs are able to respond to viral infection by recognizing 
pathogen associated molecular patterns (PAMPs). Interaction of a RNA PAMP 
with the binding domain of RIG-I induces a conformational change that allows it 
to signal to downstream pathway components and subsequently induce the 
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expression of IFN (10, 39, 120).  Recent structural analysis shows that blunt 
ended dsRNA containing a 5’trihosphate (5’PPP) is the most potent stimulator of 
RIG-I, although RNA lacking a 5’PPP can stimulate as well, despite a much 
weaker binding affinity (76, 84, 105, 106).  Additionally, studies indicate that 
regions of dsRNA are required for strong binding, as affinity between RIG-I and 
ssRNA is poor.  Poor binding affinity results in the inability to stimulate the RIG-I 
response, and indeed ssRNA is not stimulatory in vivo.  This is not surprising, as 
many host cellular RNAs are single stranded.  However, one model of RIG-I 
activation states the weak affinity for ssRNA allows RIG-I to constantly sample 
RNA within the cell, but only initiate antiviral signaling upon recognition of a 
PAMP structure (personal communication, Michael Gale).  Thus, RNA with 
secondary structure and a 5’PPP is the most potent stimulator of the antiviral 
response, but other RNAs are also capable of binding to and possibly activating 
RIG-I.   
Previous studies have demonstrated WNV is recognized by RIG-I during 
infection (53) and in chapter 2, we determined that several regions of the WNV 
genome and antigenome are capable of inducing a RIG-I mediated antiviral 
response.  However, the specific structural features of WNV RNA involved in 
RIG-I activation still remain unknown.  In order to gain further perspective on the 
RIG-I mediated antiviral response to WNV, we analyzed the structure and 
binding interactions with one of the identified PAMPs, the 5’UTR, utilizing 
selective 2’-hydroxyl acylation analysis by primer extension (SHAPE).  SHAPE 
utilizes an electrophile, such as 1-methyl-7-nitroisatoic anhydride (1M7), to 
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selectively form adducts at the 2’hydroxyl position of RNA nucleotides that are 
unconstrained by base pairing.  These adducts are identified as positions during 
primer extensions.  The reverse transcriptase pauses, producing a product that is 
shifted one base upstream of the adduct-containing nucleotide.  The product can 
then be resolved via denaturing polyacrylamide gel electrophoresis (PAGE) (115, 
201, 202). Additionally, we sought to compare the structure of and the RIG-I 
response to the 5’UTR of a nonpathogenic viral strain, WNV-Madagascar78 
(WNV-MAD78), as well as variations of the WNV-NY 5’UTR, including both a 
mutated and truncated RNA.    
Our findings suggest that the WNV 5’UTR contains both secondary 
structural elements and regions of single stranded RNA.  Additionally, both the 
WNV-NY and WNV-MAD78 5’UTR appear to be structurally similar and 
stimulated the RIG-I response to similar degree, despite a difference in 
sequence.  Further analysis of RIG-I stimulation using mutated or truncated 
5’UTRs revealed different stimulatory capacities.  Despite the differences in 
stimulatory capacity between our RNAs, the steady state binding to RIG-I was 
not significantly different, indicating that binding of RIG-I to an RNA ligand alone 








 The WNV 5’UTR is highly structured 
Our previous studies demonstrated that the WNV 5’UTR was capable of 
stimulating a RIG-I-mediated immune response.  To understand the molecular 
determinants of the RIG-I response, we further analyzed the WNV 5’UTR through 
structural probing and binding assays with RIG-I. Several studies have provided 
predicted secondary structure models and mutational analysis has confirmed 
some of the predicted structures.  However, structural probing of this RNA has 
yet to be performed. We analyzed the structures of different forms of the WNV 
5’UTR, including the 5’UTR of the pathogenic WNV-NY, the nonpathogenic 
WNV-MAD78, and a mutated WNV-NY predicted to form a single SL structure 
(Figure 16).   
We began by analyzing the full length (1-97nt) WNV 5’UTR (Figure 16 A).  
Resolution of our SHAPE reaction by PAGE revealed several de-protected bases 
at the 3’ end of the fragment, primarily between bases 50 and 80.  This region 
contained bases both strongly and weakly de-protected.  There were additional 
de-protected bases clustered around base position 90, however, these bases 
were only weakly de-protected. 
The 5’UTRs of different WNV strains are nearly identical and have been 
reported to contain the same secondary structures.  However, there is a single 
base deletion at position 51 in the non-pathogenic WNV-MAD78 5’UTR as 
compared to a pathogenic WNV-NY strain.  This small sequence difference may 
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contribute to a difference in the structures formed by the 5’UTR and result in 
differences in RIG-I binding.  Therefore we probed the secondary structure of the 
WNV-MAD78 5’UTR using SHAPE (Figure 16B).  The pattern of de-protected 
bases was similar to that seen with the WNV-NY, with several bases between 
positions 50 and 70 being de-protected, although only weakly.  
In addition to examining the pathogenic and non-pathogenic strains of 
WNV, we also probed the structure of a WNV-NY 5’UTR mutated to form a single 
predicted SL structure (WNV-NY-SL).  The SHAPE of WNV-NY-SL revealed 
several de-protected bases that suggest a stem loop (Figure 16C). 
 
Figure 16: SHAPE analysis of the WNV 5’UTR.  2pmol of RNA was incubated with 1M7 (+) or 
DMSO (-) and then subjected to primer extension by reverse transcription.  Products were 
analyzed by PAGE on a denaturing 8% polyacrylamide gel.  A) WNV-NY 5’UTR.  B) WNV-
MAD78 5’UTR.  C) WNV-NY 5’UTR predicted to form a single stem loop (SL). 
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In order to fully understand the implications of our SHAPE data, we next 
examined the data when mapped to the predicted secondary structures of our 
various RNAs.  SHAPE of the WNV-NY 5’UTR results were mapped to 
secondary structure predictions generated using both the Nupack and mFold 
structure prediction program (Figure 17A & B).  Structures that have been 
previously reported were generated using the MFold program.  Nupack takes 
tertiary interactions into account when predicting folding, while MFold does not. 
When aligned to the predicted structures, the data suggests that there are 
regions that are de-protected, but these bases do not align to the previously 
proposed structures (25, 95, 171).  This may indicate that there are tertiary 
interactions protecting bases, or that a stem loop structure is present but not in 
the location that was previously predicted.  Regardless, several de-protected 
bases clustered near each other may result in an area of ssRNA, such as the top 
of a stem loop or a bulge within the hairpin structure.  A majority of the de-
protected bases are only weakly de-protected, as indicated by the grey circles, 
suggesting that interactions with these bases may be fluid and not produce a 
strong structure. The presence of only a limited number of de-protected bases 
suggests that the structure forms complex interactions, preventing adduct 









Figure 17: The WNV-NY 5’UTR forms tertiary interaction and contains ssRNA 
regions. Structural predictions were produced using the Nupack (211) (A) and Mfold 
(216) (B) prediction softwares.  Black circles indicated strongly deprotected bases, gray circles 
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SHAPE analysis of the WNV-MAD78 5’UTR reveled a structure that was 
similar to the structure of the WNV-NY 5’UTR.  When the SHAPE data was 
mapped to the predicted structures generated by Nupack and Mfold, the data 
indicated that, as with the WNV-NY 5’UTR, several bases are de-protected 
between positions 50-80nt (Figure 18A & B).  The absence of any other de-
protected bases suggests that there may also be tertiary interactions within the 
WNV-MAD78 5’UTR.  One difference between the structures is the absence of 
de-protected bases clustered around base position 90, within the region 
predicted to form SLB, suggesting this SL is absent or buried in a tertiary 
interaction in the WNV-MAD78 5’UTR. 
The WNV-MAD78 5’UTR is capable of stimulating an antiviral 
response. 
The structures appear to be similar between the WNV-NY and -MAD78 
strains but RIG-I stimulation has not been tested for the WNV-MAD78 5’UTR.  In 
order to determine whether there is a difference in the RIG-I response between 
the two 5’UTRs, we compared RIG-I stimulation using a luciferase reporter assay 
(Fig 19).  Huh7 cells were transfected with a RIG-I dependent luciferase reporter, 
ISG56-luc Cells were subsequently infected with a potent inducer of the RIG-I 
specific antiviral response, SenV, or transfected with RNA corresponding to 
either the WNV-NY or -MAD78 5’UTR.  The WNV-MAD78 5’UTR stimulated a 
RIG-I-mediated antiviral response that was similar to the response observed with 
the WNV-NY 5’UTR. Thus the structural differences seen between the two RNAs 
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Figure 18: The WNV-MAD78 5’UTR forms tertiary interaction and contains ssRNA 
regions.  Structural predictions were produced using the Nupack (A) and Mfold (B) prediction 
softwares.  Black circles indicated strongly deprotected bases, gray circles indicate weakly 
deprotected bases.  Predictions are given for structures with the lowest minimum free energy. 
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Figure 19: RIG-I stimulation is similar between the WNV-NY and WNV-MAD78 5’UTRs. Huh7 
monolayers were transfected with pISG56-luc and pCMV-Renilla 16 hr prior to infection with 
SenV or transfection with 500 ng of the indicated RNAs in triplicate.  Cell lysates were prepared 8 
hr post transfection and assayed for luciferase activity.  Values represent the average luciferase 
expression compared to mock (± standard error) from a minimum of two independent 
experiments.  Statistical analysis was performed using Dunnett’s multiple comparison analysis, * 
p<0.05, ** p<0.01 *** p<0.001. 
 
Mutation of the NY 5’UTR to form a single stem loop reduces its RIG-I 
stimulatory capacity 
Our analyses of the WNV-NY and WNV-MAD78 5’UTRs suggested that 
these regions contain both a stem loop secondary structure and tertiary 
interactions.  Additionally, these structures may result in regions of ssRNA.  Our 
finding that RNAs containing these structures stimulates RIG-I expands on work 
from previous groups, who have demonstrated that RNA with a blunt-ended stem 
loop structure stimulates a robust RIG-I response (12, 146, 157). SHAPE 
analysis of the mutated 5’UTR SL suggested that the RNA formed a stem loop 


































predicted stem loop structure, which were virtually identical, the SHAPE data 
suggested that while the structure may form a stem loop, some bases may be 
involved in tertiary interactions, as suggested by the limited number of de-
protected bases present (Figure 20).  Also, The suggested structure appears to 
lack any significant regions of ssRNA, however.   
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Figure 20: The WNV-NY-SL forms a complex structure. A structural prediction was produced 
using the Nupack A) and mFold B) structural prediction software.  Black circles indicated strongly 
deprotected bases, gray circles indicate weakly deprotected bases.  The prediction is given for 
structures with the lowest minimum free energy. 
In order to examine the influence of the structures identified in WNV-NY 
and WNV-MAD78 on the ability of RIG-I to respond to the 5’UTR, we examined 
the ability of the mutated WNV-NY-SL 5’UTR to stimulate RIG-I using a 
luciferase reporter assay (Figure 21). The WNV-NY-SL 5’UTR was able to induce 
stimulation of the RIG-I response, but the response was reduced compared to 
that observed by wild type WNV-NY 5’UTR RNA. 
	  
 
Figure 21: Stimulation by the WNV-NY-SL is reduced as compared to WNV-NY.  Huh7 
monolayers were transfected with pISG56-luc and pCMV-Renilla 16 hr prior to infection with 
SenV or transfection with 500 ng of the indicated RNAs in triplicate.  Cell lysates were prepared 8 
hr post transfection and assayed for luciferase activity.  Values represent the average luciferase 
expression compared to mock (± standard error) from a minimum of two independent 
experiments.  Statistical analysis was performed using Dunnett’s multiple comparison analysis, * 





































Truncation of the NY 5’UTR to fewer than 80 nucleotides abolishes 
RIG-I signaling capacity 
 To define the minimal stimulatory element in the 5’UTR, we generated 3’ 
deletion mutants of WNV-NY 5’UTR in order to determine the minimum number 
of bases required for induction of the RIG-I response (Figure 22A) and analyzed 
their stimulatory capacity using a luciferase reporter assay (Figure 22B).  While 
the 90 nucleotide 5’UTR construct retained its stimulatory capacity, the 80 
nucleotide construct did not.  Structural predictions were generated of the 
truncation mutants in order to determine if there are any readily identifiable 
structural variances between the 1-80nt fragment and the 1-90nt fragment to 
account for the differences in stimulatory capacity.  The 1-90nt fragment is 
predicted to form a tertiary interaction, but is not predicted to contain a region of 
ssRNA (Figure 23A).  The 1-80nt fragment is also predicted to contain some 
tertiary interaction, which occurs in the middle of a ssRNA bulge.  However, the 
interaction at this position is only mediated by 3 bases and is therefore 
considered to be very weak.  Given the weakness of this interaction, the tertiary 





Figure 22:  Truncation of the WNV-NY 5’UTR affects stimulation of RIG-I.  A) Diagram 
illustrating the truncations produced of the WNV-NY 5’UtR.  B) Huh7 monolayers were 
transfected with pISG56-luc and pCMV-Renalla 16 hr prior to infection with SenV or transfection 
with 500 ng of the indicated RNAs in triplicate.  Cell lysates were prepared 8 hr post transfection 
and assayed for luciferase activity.  Values represent the average luciferase expression 
compared to mock (± standard error) from a minimum of two independent experiments.  
Statistical analysis was performed using Dunnett’s multiple comparison analysis, * p<0.05, ** 














































































    
Figure 23: Truncation of the WNV-NY 5’UTR is predicted to alter the secondary structures.  
Structural predictions were made of the WNV-NY 1-90nt (A) and WNV-NY 1-80nt (B) fragments 
using the Nupack structure prediction software.  Predictions are given for structures with the 
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Binding affinity of the WNV 5’UTR for RIG-I does not correlate with 
stimulatory capacity  
 In order to determine whether RIG-I activation correlated to binding of 
RIG-I to RNA, we examined the steady state binding of RIG-I to the various RNA 
species using the newly described Differential Radial Capillary Action of Ligand 
Assay (DRaCALA) (Figure 24) (46, 144, 147).  DRaCALA is based on the 
principle that proteins are immobilized in a nitrocellulose matrix, while RNA will 
diffuse.  Radiolabeled RNA bound to a protein will be localized in the center of 
the diffusion circle, creating a dark spot within the center of the total circle The 
fraction bound can be calculated by determining the fraction of signal retained in 
the central circle as compared to the total signal and the dissociation constant 
(Kd) of the reaction determined by plotting fraction bound versus protein 
concentration.  The Kd for the full length WNV-NY, WNV-MAD78 5’UTR and the 
mutated WNV-NY-SL were determined to be 270 nM ± 50 nM ~800 nM ± 130 nM 
and ~500 nM ± 100 nM, respectively.  When the binding curves of WNV-NY and 
WNV-MAD78 were compared, the total fraction of RNA bound was higher in 
WNV-MAD78, at ~30%, than the WNV-NY, which was only at 20%, despite the 
fact that the WNV-NY had a lower Kd (Figureure 25A).  In contrast, comparison 
of the WNV-NY and the WNV-NY-SL indicated that the total fraction bound in 
both samples was similar, at ~20%, despite WNV-NY having a lower Kd.  This 
suggests that while affinity for the WNV-MAD78 is lower, the total amount of RNA 
bound is greater than for WNV-NY or WNV-NY-SL.  The differences seen in 
stimulation as related to binding affinity may indicate that stimulation of RIG-I, 
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which was similar between the WNV-MAD78 and WNV-NY, is not solely 
determined by binding affinity but can also be influenced by the percent of RNA 
that is bound.  
 We next examined the steady state binding of the WNV-NY 5’UTR 
truncations using DRaCALA (Figureure 26).  The Kd of 1-80nt fragment was ~ 
200 nM ± 50 nM, while the Kd of the 1-90nt fragment was much higher, at 
~420nM ± 50 nM (Figureure 26).  Comparison of the binding curves between full 
length WNV-NY (1-97nt), the 1-90nt fragment and the 1-80nt fragment revealed 
that while the Kds of the WNV-NY and the 1-90nt fragments were higher than the 
1-80nt fragment, the total fraction bound for the 1-80nt fragment was less.   
Overall, the differences in Kd observed between the RNA species 
examined do not correlate with stimulation.  This suggests that while slight 
structural differences may exist between the analyzed 5’UTR fragments, and 
these fragment have differential stimulatory capacity, the differences are not 









Figureure 24: Representative DRaCALA images used for Kd determination.  Purified RIG-I 
was incubated with the indicated radiolabeled RNAs and Differential Radial Capillary Action of 
Ligand Assays were performed.  Protein-RNA complexes were spotted onto nitrocellulose and 
examined using a FLA-5000 phosphoimager.  Protein concentrations were consistent between 
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Figureure 25:Steady state binding of RIG-I to the WNV-NY 5’UTR is similar to WNV-MAD78 
and WNV-NY-SL.  Purified RIG-I was incubated with the indicated radiolabeled RNAs and 
Differential Radial Capillary Action of Ligand Assays were performed.  Protein-RNA complexes 
were spotted onto nitrocellulose and examined as compared to WNV-MAD78 (A) and WNV-NY-





Figureure 26: Steady state binding of RIG-I to the full length WNV-NY 5’UTR RNA is similar 
to the 1-90nt fragment but not the 1-80nt fragment. Purified RIG-I was incubated with the 
indicated radiolabeled RNAs and Differential Radial Capillary Action of Ligand Assays were 
performed.  Protein-RNA complexes were spotted onto nitrocellulose and examined.  Values are 
representative of duplicate biological replicates performed at least in triplicate. 
 
 




















































The WNV C(+) RNA does not bind to RIG-I 
In order to confirm RIG-I/RNA binding was specific in our DRaCALA 
experiments, we examined the steady state binding of a non-stimulatory WNV-
NY RNA, C(+) (Chapter 2).  The WNV-NY C(+) RNA did not induce RIG-I 
stimulation in our previous assays.  If stimulation is dependent on specific binding 
by RIG-I, the C(+) should not bind, and indeed our data indicates that the binding 
is non-specific (Figureure 27).  The non-specific binding of C(+) to RIG-I, which 
was unable to stimulate the RIG-I response, confirms that the binding observed 
with our 5’UTR species is specific. 
 
 
Figureure 27: RIG-I binding of WNV C(+) is non-specific.  Purified RIG-I was incubated with 
the indicated radiolabeled RNAs and Differential Radial Capillary Action of Ligand Assays were 
performed.  Protein-RNA complexes were spotted onto nitrocellulose and examined.  Values are 
representative of duplicate biological replicates performed at least in triplicate. 
 
Discussion 
















 Stimulation of the RIG-I mediated antiviral response is an important step in 
controlling viral infection.  The ability of the host to respond rapidly to infection 
can influence disease outcome.  In the case of WNV, different strains of the virus 
demonstrate variable levels of pathogenicity.  The factors that influence this 
difference are poorly understood, but may include differences in innate immune 
response to the virus, as previous work has demonstrated different disease 
outcomes can be dependent on the immune response to WNV (40, 85, 185, 
195).  In order to define the structures that are important for RIG-I recognition of 
WNV PAMPs, we performed structure probing and binding studies of the WNV 
5’UTR, a previously determined viral PAMP.  
 SHAPE analysis provided insight into the structure formed by an 
established RIG-I PAMP, the WNV 5’UTR.  Structure probing suggested that 
both the WNV-NY and WNV-MAD78 5’UTRs formed structures in which few 
bases were de-protected, suggesting complex tertiary interactions occur within 
these RNAs, and that only small regions of ssRNA were present.  Furthermore, 
only minor differences in structure were suggested between the WNV-MAD78 
and WNV-NY 5’UTRs as a result of a single nucleotide deletion from WNV-
MAD78, and there was no difference in the ability of WNV-MAD78 5’UTR to 
stimulate RIG-I.  Thus RIG-I is likely interacting with conserved structural 
elements between the NY and MAD78 5’UTRs.  Additionally, ssRNA regions may 
be an important factor in RIG-I interaction, as regions of ssRNA were suggested 
in both the WNV-NY and WNV-MAD78 5’UTR, but not in the WNV-NY-SL.  
Structural probing suggested that the WNV-NY-SL RNA may also contain tertiary 
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interactions similar to the WNV-NY and –MAD78 RNA, which may account for 
the ability of this RNA to stimulate RIG-I, albeit less robustly. WNV-NY 5’UTR 
truncation mutants were predicted to contain tertiary interactions.  However, the 
predicted interaction in the 1-80nt fragment was very weak, with only 3 bases 
interacting, thus tertiary interactions may be lost during normal RNA breathing.  If 
the tertiary interactions within this RNA are lost, this also creates a significant 
ssRNA bulge, which was predicted to be absent in the 1-90nt fragment.  The 
inability of the 1-80nt fragment to stimulate suggests that even if this ssRNA 
bulge is sufficient for binding, tertiary interactions are required to induce 
signaling, as the 1-80nt fragment did not stimulate RIG-I.  Structure probing of 
the 1-80nt and 1-90nt fragments will help to clarify the structural requirements 
necessary to stimulate RIG-I.  
 When the binding of the RNA species to RIG-I was analyzed, the Kds 
were higher than previously reported Kd values for RIG-I ligands.  A blunt-ended 
14 bases dsRNA was shown to have a Kd of 5 nM (84), as compared to the 
WNV-NY 5’UTR, at ~270nM.  This increase in the Kd value may be a reflection of 
the increased length of the RNA, as the NY 5’UTR is 97 bases in length.  Size 
alone does not account for the ability of RIG-I to bind or be stimulated by an 
RNA, however, as truncation of the NY 5’UTR to 80 nucleotides in length 
abolished signaling, while decreasing the Kd.  Crystal structures of RIG-I bound 
to RNA have revealed that only 9 base pairs of the dsRNA bound can fit in the 
RIG-I binding pocket, with the remaining sequence extended out beyond (76, 84, 
94, 106). This suggests that the structures adopted by the various 5’UTR species 
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are influencing how the region of RNA that is bound within this binding pocket are 
able to interact.    
Another possible explanation of the differential binding and stimulation 
seen amongst the RNA species examined is due to the limited number of bases 
required in order to facilitate binding.   Multiple copies of RIG-I have been shown 
to bind to a single RNA molecule, especially those of longer length (<200nt) (18, 
136).  It is possible that the structural confirmation adopted by those RNAs that 
show more stimulation of the RIG-I response allow for a greater number of RIG-I 
proteins to bind, thus increasing the signaling strength to the downstream target 
IPS-1.   Binding to internal regions of the dsRNA molecule have been shown to 
have a much lower affinity than binding interactions which occur at the 5’ end of 
the molecule (76).  This weak binding affinity is proposed to facilitate RIG-I 
binding to RNA in order to “scan” for PAMP characteristics, thereby enabling 
RIG-I to survey the cell without being in a signaling-active state.  The weak 
affinity for RIG-I associated with the examined RNAs may indicate one or both of 
these mechanisms of RIG-I binding and stimulation may be contributing to the 
induction of the antiviral response.  
 This study examined the structure of RIG-I specific WNV PAMPs and 
assed the steady state binding of these WNV PAMPs to RIG-I.  Our data 
suggests that affinity is not necessarily a reflection of stimulatory capacity and 
that structures present or absent within the PAMP RNA can greatly alter the 
ability of RIG-I to induce a response. 
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The DExD/H-box helicases belong to a large group of proteins within the 
superfamily 2.  The members of this family are generally involved in a variety of 
roles related to RNA metabolism.  One DExD/H-box helicase that has been 
recently defined is DDX3.  DDX3 has been shown to be involved in a variety of 
normal cellular processes involving RNA, including mRNA splicing and export 
from the nucleus, regulation of both transcription and translation, and RNA decay 
(28, 57, 68, 90, 91, 161).  Due to its involvement in a wide variety of cellular 
processes, especially RNA processing, DDX3 can be localized to both the 
nucleus and cytoplasm and is constitutively expressed. DDX3 contains both a 
helicase domain and an ATPase domain (82), similar to other DExD/H-box 
helicases, such as the pattern recognition receptors (PRRs) RIG-I and MDA5.  
However, RIG-I and MDA5 also contain a CARD-signaling domain, which is 
necessary to initiate the antiviral response to viral RNA 
Due to the variety of cellular functions performed by DDX3, it makes an 
attractive target for viruses, and has been shown to be co-opted to serve as a 
pro-viral protein, as well as as regulated to limit anti-viral activities.  For example, 
HIV and HCV have both been shown to utilize DDX3 for replication.  HIV takes 
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advantage of DDX3’s role in mRNA export from the nucleus.  The viral Rev 
protein acts in concert with DDX3 to export the HIV mRNA into the cytoplasm 
(100, 123).  Although the specific role that DDX3 plays in this export is not fully 
understood, the helicase domain of DDX3 is required in order to achieve proper 
export.  The requirement of a functional helicase suggests that DDX3 may have 
a role in disrupting secondary structures within the viral RNA prior to export 
(207). The HCV core protein has been shown by several groups to interact with 
the C-terminal domain of the DDX3 protein (5, 131, 133).  Further studies have 
suggested that the interaction between the core and DDX3 is critical for the virus, 
and it has been suggested that helicase function of DDX3 may be important in 
unwinding the viral RNA to facilitate replication.  There is also work to suggest 
that direct interaction of the core with DDX3 is not required for replication, as 
mutation in core that disrupt its interaction with DDX3 did not affect the 
production of viral RNA or infectious particles (4).   However, further data from 
this study indicated that knock down of DDX3 in cells infected with a virus unable 
to bind to DDX3 resulted in a reduction in viral particles and RNA replication, 
indicating that DDX3 is necessary for HCV replication.  Thus, the requirement for 
interaction between the HCV core and DDX3 is still unclear, although the 
predominance of evidence suggests that DDX3 is necessary for HCV replication.   
DDX3 has also recently been implicated in serving in an antiviral capacity 
through the innate, intracellular antiviral response. Recent studies have begun to 
define an antiviral role of DDX3 as both a sensor of viral RNA and as an 
interacting partner of several proteins involved in the downstream RIG-I/MDA5 
	  
73	  
and TLR3 signaling cascades.  It was first noted that vaccinia virus encodes a 
protein, K7, which serves to inhibit several of the PRR proteins, also targets 
DDX3 (78).  Additionally, it was demonstrated that knock down of DDX3 during 
vaccinnia virus infection led to a decrease in IFN-β expression.   This suggested 
that in addition to a role in RNA processing and production, DDX3 may also have 
antiviral activity.  Later studies found DDX3 co-immunoprecipitates with the 
TBK1/Ikke protein complex, which is activated by both RIG-I and TLR3 signaling 
(163).  Further studies have demonstrated that DDX3 can bind synthetic RNA 
(polyI:C) as well as short double stranded RNA segments, giving it a potential 
role as an RNA sensor (132).  A role in antiviral activity is further supported by 
the observation that, in contrast to RIG-I and MDA5, which are expressed at low 
levels in the cell, DDX3 is constitutively expressed.  Therefore, DDX3 is present 
at high enough levels to serve as an initial RNA sensor or interacting partner to 
other cellular PRRs.   Indeed, DDX3 has been shown to interact with both RIG-
I/MDA5 and IPS-1 to enhance the RIG-I mediated response.  Finally, there is 
also some evidence implicating DDX3 as a transcription factor, as DDX3 was 
shown to associate with the IFN-β promoter.   
This mounting evidence supports the role of DDX3 as either an initial 
sensor of RNA or an enhancer of the antiviral response during viral infection.  
Although DDX3 may be an important component of the innate intracellular 
immune response, its role as an RNA sensor and mediator of the antiviral 
response has not been clearly defined for a number of viruses. We therefore 




 DDX3 co-localizes with WNV proteins during infection 
 DDX3 has been shown to interact with HCV core protein in order to 
promote viral replication.  Therefore, we assessed whether DDX3 co-localized 
with WNV proteins.  Mock- or WNV-infected cells were examined for protein 
localization by immunofluorescence assay (IFA) at 24 hours post infection 
(Figure 30).  In two different cell types, 293T (Figure 28A) and Huh7 (Figure 28B) 
cells, DDX3 was observed in the cytoplasm in mock infected cells.  In both cell 
types, at 24 hours post WNV infection, DDX3 could be detected in both the 
cytoplasm and the nucleus.  Additionally, DDX3 proteins appear to be co-
localized with WNV proteins, and the relative intensity of the DDX3 staining was 
enhanced when it colocalized with WNV protein (white arrows) as compared to 
the DDX3 intensity in un-infected cells.  This suggest that WNV proteins may 
interact with DDX3 at 24 hpi. 
  
 
DDX3 does not a have pro-viral effect during WNV infection 
Due to the apparent co-localizaiton of DDX3 with WNV proteins, we 
examined if DDX3 may have pro-viral effects during infection.  Therefore, we 
analyzed the effect of DDX3 expression in a WNV replicon-bearing cell line 
(Figure 29).  A BHK cell line harboring a subgenomic WNV replicon encoding a 
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renilla luciferase was transfected with DDX3.  Although lacking the structural 
genes required to produce virions, the replicon contains the 5’ UTR through to 
the CS sequence within C, and the 3’UTR, enabling viral replication and protein 
translation to take place.  The effects on viral replication and protein expression 
were examined by monitoring the production of luciferase, which would be 
enhanced if DDX3 was playing a pro-viral role. 
 
Figureure 28: WNV protein colocalized with DDX3 during infeciton in multiple cell types.  
293T cell (A) and Huh7 cell (B) monolayers were mock infected or infected with WNV-NY at an 
MOI of 1.  At the indicated time points, cells were fixed and analyzed by IFA for WNV and DDX3 
protein expression.  Cells were visualized at 40x magnification.   
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The levels of renilla luciferase produced, however, were consistent 
between mock-transfected cells and cells transfected with either an empty control 
vector or the DDX3 containing plasmid.  Therefore, additional DDX3 expression 
had no effect on replication of the viral genome or protein expression, suggesting 
DDX3 does not have a pro viral role during WNV infection.   
 
  
Figureure 29: DDX3 overexpression does not affect replication or protein expression of a 
WNV replicon.  A) Diagram illustrating the WNV replicon. Gray shading indicates WNV 
sequence.  B) BHK cells bearing a WNV replicon were transfected with 500 ng DDX3. Cell 
lysates were prepared 24 hrs post transfection and assayed for luciferase activity.  Values 
represent the average luciferase expression compared to mock (± standard error) from a  































DDX3 expression is reduced at late points post WNV infection 
 To further characterize the potential interaction of DDX3 with WNV, we 
examined if DDX3 protein levels change over time during infection.  Cell lysates 
from WNV-NY infected 293T cells were probed with DDX3 and WNV antibodies 
(Figure 30). DDX3 protein levels decreased between 48 and 72 hours post 
infection.   Although this time point also corresponds with a high degree of cell 
death within this cell type, levels of the loading control, GAPDH, are still 
consistent at 72 hours.  This data suggests that DDX3 expression may be 
modulated at very late points post WNV infection in this cell type. 
     
Figure 30  DDX3 expression is reduced by late points in WNV infection.  293T cells were 
mock infected or infected with WNV-NY at an MOI of 1.  Lysates were collected at the indicated 
time points and subjected to immunoblot analysis.  Blots were examined for DDX3, WNV and 


















Overexpression of DDX3 does not alter viral replication or the 
antiviral response 
DDX3 appears to localize with WNV proteins, and DDX3 protein levels 
appear to decrease over time in the cell, indicating that WNV may be negatively 
regulating DDX3 expression.  As DDX3 is proposed to play a role in the antiviral 
response, we wanted to determine if DDX3 overexpression was capable of 
inducing an antiviral state through interaction with IPS-1.  We examined the 
effect of overexpression of DDX3 and IPS-1 together in the presence of IRF3-
inducible luciferase reporter construct (Figure 31A).  In cells transfected with IPS-
1 alone, the RIG-I response was stimulated, but DDX3 alone did not induce 
luciferase expression.  However, in cells co-transfected with IPS-1 and DDX3, 
there is an increase in luciferase expression, indicating that DDX3 expression 
was capable of enhancing an IPS-1 stimulated antiviral response.    
We next examined the affect of DDX3 overexpression in cells infected with 
WNV to determine whether increasing available DDX3 would enhance the 
antiviral response to WNV.  We infected DDX3 overexpressing cells with WNV at 
an MOI of 1 (Figure 31B & C).  DDX3 overexpression did not alter ISG56 protein 
levels, an antiviral protein directly induced as a result of IPS-1 activation.  
Additionally, there was no difference in the expression of WNV protein at either 
24 or 48 hours post infection in either the vector expressing or DDX3 expressing 
cells (Figure 33 B).  Overexpression of DDX3 also had no effect on WNV titers at 
24 or 48 hours post infection (Figure 33C). Thus, overexpression of DDX3 did not 
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alter the antiviral response to WNV, nor did it enhance viral replication, further 
supporting the data that DDX3 is not pro viral. 
 
 
Figure 31:  DDX3 overexpression does not affect the antiviral resopnse to WNV infection 
or viral replication.  A) Huh7 cells were transfected with IPS-1, DDX3 and pISG56-luc in 
triplicate.  Cell lysates were prepared 24 hrs post transfection and assayed for luciferase activity 
as described in Figure 7.  B, C) 293T cells were mock infected or infected with WNV-NY at an 
MOI of 1.  Cell lysates were collected for immunoblot analysis (B) and supernatants were 
collected for viral plaque assay (C) at the indicted time points post infection.  All values are 
representative of duplicate experiments. 
 
Discussion 
 DDX3 carries out a number of functions related to RNA production, 
transport and degradation, and is therefore a potential target for exploitation by 
viruses.  It has also been implicated as a component of the RIG-I mediated 
antiviral pathway, and even as a PRR itself.  Several viruses have been shown to 
actively impede the antiviral activity of DDX3.  The vaccinia virus K7 protein 
targets DDX3 by directly binding to it, preventing it from interacting with the 
Ikkε/TBK1 complex and activating IRF3 and consequently inducing IFN-β 
expression (78, 128).  Other viruses such as HIV and HCV utilize DDX3 in their 
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life cycle.  HIV takes advantage of the function of DDX3 in export of RNA from 
the nucleus.  The viral Rev protein acts in concert with DDX3 and the cellular 
CRMI protein to export un-spliced and/or partially spliced viral RNAs from the 
nucleus, an essential part of the HIV replication scheme (100, 123, 207).   HCV is 
suggested to require DDX3 for viral replication, although the specific 
mechanisms underlying this requirement are still unknown (5).  DDX3 has also 
been shown to interact directly with the core protein, although it is unclear if this 
interaction is required for viral replication (4, 133).  There is some data to indicate 
that binding of the HCV core protein prevents DDX3 from interacting with IPS-1 
and thereby impedes the antiviral transduction pathway (131).  Here we 
evaluated the role DDX3 may play during the course of WNV infection.   
We first sought to characterize its localization and determine the affect of 
DDX3 on viral replication.  DDX3 appeared co-localized with WNV protein by 
IFA, suggesting that WNV may be interacting with DDX3.  One of the most 
recently defined roles of DDX3 is as a component of the translation pre-initiation 
complex.  DDX3 binds to the translation complex component eIF4G within stress 
granules; therefore it is possible that co-localization of DDX3 with WNV proteins 
is simply due to the fact that as infection progresses, more DDX3 is recruited to 
and is found to interact with WNV proteins as a consequence of viral translation.  
When DDX3 was overexpressed in a cell line containing a WNV replicon 
encoding renilla luciferase, there was no increase in the production of renilla, 
suggesting that WNV does not utilize the increased available DDX3 to enhance 
replication or protein translation.  However, the cells containing the replicon are 
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BHK cells, a hamster kidney line, and therefore it is possible that the human 
DDX3 used in the experiment does not properly interact with the hamster 
translation proteins.  This seems unlikely, however, as the sequence 
conservation between the hamster and human DDX3 proteins is 100% on the 
amino acid level.  Even so, examining the ability of DDX3 to promote WNV 
protein translation in a human cell line would ensure that the results were not 
influenced by potential differences between the human and hamster cellular 
proteins. 
Another proposed role for DDX3 is as an enhancer of the antiviral 
response, and so we examined the ability of DDX3 expression to enhance the 
IPS-1 mediated antiviral response. Expression of DDX3 and IPS-1 together 
enhanced IPS-1 activation of IRF-3, indicating that DDX3 is able to contribute to 
this antiviral pathway.  This is consistent with previous work demonstrating that 
DDX3 interacts directly with IPS-1, and this interaction enhances IFN-β promoter 
expression (132).  However, when the expression of the IRF3 inducible antiviral 
protein ISG-56 was monitored in DDX3 overexpressing cells, there was no 
difference in the protein levels between those infected with WNV infected and 
mock-infected.  The similar levels of ISG-56 suggest that overexpression of 
DDX3 is unable to enhance the antiviral response during WNV infection.  
Repetition of these IPS-1/DDX3 co-transfection experiments in the context of a 
WNV infection would revel if WNV prevents DDX3 from interacting with IPS-1 in 
the antiviral response, either directly or as a consequence of utilizing DDX3 for 
other functions related to viral replication.   
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We also examined the effects of overexpression of DDX3 on viral 
replication and viral protein production. We observed no difference in WNV viral 
protein expression or viral replication when DDX3 was overexpressed, further 
suggesting that DDX3 does not play a pro-viral role during WNV infection.  The 
decrease in DDX3 expression at 72 hours post infection suggests that WNV is 
negatively regulating DDX3 protein expression.  One possibility is that as 
infection progresses, the cell begins to respond by inducing the degradation of 
viral proteins.  The Jab1 protein has been shown to associate with the WNV C 
protein, resulting in the export to the cytoplasm and eventual degradation of C 
(129).  Given that DDX3 has been shown to bind to the related HCV C, it is 
possible that DDX3 binds the WNV C protein as well.  If this is the case, it may 
be that DDX3 is degraded as a consequence of association as is the case with 
Jab1 induced degradation of WNV C.  Identification of which viral or cellular 
proteins DDX3 is bound to or associates with will begin to clarify why there is a 
reduction in protein level at late times in infection. 
DDX3 was observed to co-localize with and WNV proteins at 24 hours 
post infection.  While there is no indication that this interaction is antiviral, it is 
possible that by this point in infection the virus has already subverted any 
antiviral activity DDX3 possess.  It is also possible that the virus is utilizing DDX3 
specifically for its role as a component of the ribosome/translational machinery or 
one of its other RNA-related cellular functions at this point in infection.  In order to 
determine if DDX3 is interacting with other antiviral proteins during WNV 
infection, DDX3 protein expression and localization patterns should be examined 
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in relation to other antiviral pathway components, especially the RIG-I pathway 
members via immunofluorescence.  Likewise, analysis of co-immunoprecipitation 
experiments to see what binding partners DDX3 is associated with during WNV 
infection could help identify which cellular proteins or the specific WNV protein 
DDX3 is interacting with during infection. 
Experiments utilizing the overexpression of DDX3 failed to increase the 
antiviral response or reduce the viral titer to any significant level.  This is not to 
say, however, that knock down of the protein would not have more readily 
apparent consequences during infection.  Indeed, other studies have looked at 
the knock down of processing body (p-body) associated proteins, including 
DDX3, during WNV infection and found a correlation to viral replication (27).  P-
bodies are vesicles formed as a consequence of cellular stresses, including viral 
infection, where mRNA is stored and degraded.  When DDX3 was knocked 
down, there was a reduction of WNV viral RNA replication and the production of 
viral particles.  Repeating experiments to analyze whether the absence of DDX3 
during infection can affect the antiviral response would clarify the role this protein 
is playing during WNV infection. 
Our work thus far suggests that DDX3 may co-localize with WNV protein 
and that WNV infection affects DDX3 protein levels by late time points during 
infection.  However, the protein does not appear, according to our initial 
experiments, to possess a clear pro- or antiviral function.  The precise role of 
DDX3 during WNV infection remains unknown, and its potential involvement as 
an antiviral cascade partner or viral RNA sensor has yet to be defined.  Further 
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studies to examine the antiviral potential of DDX3 will need to be performed in 



















Chapter 5 – Discussion  
 
Within the past decade, WNV has established itself as a serious public 
health concern within the United States.  The increased incidence of neurological 
disease combined with the establishment of yearly epidemics has made gaining 
a full understanding of the factors that contribute to virulence a priority.  The host 
response to a viral infection can be critical in defining the severity of infection.  A 
rapid and robust antiviral response, such as that mediated by the PRR RIG-I, can 
serve to constrain viral replication at the site of infection and trigger activation of 
the adaptive immune response to promote viral clearance   thereby, moderating 
disease symptoms.  The RIG-I response is a critical component of the innate 
immune response to WNV infection, but as with many other viruses, the PAMPs 
activating this pathway remain undefined.  The work described in this dissertation 
begins to define the components of the WNV genome and antigenome that serve 
as viral PAMPs recognized by RIG-I.  Additionally, these studies begin to provide 
insight into the RNA structures that may be involved in activating RIG-I.  This 
work also describes preliminary data analyzing the role of DDX3, a protein with 
proposed antiviral activity associated with the RIG-I response, during WNV, 
although the exact function of the protein remains to be defined.  
Identification of WNV-NY PAMPs 
This work has defined several regions of the WNV genome capable of 
serving as PAMPs during infection.  The 5’UTR and NS2a from the positive 
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sense genome and the 3’UTR, E NS2a and NS4a of the negative sense 
antigenome were all capable of stimulating a RIG-I mediated antiviral response.  
However, incorporation of these regions into larger RNA fragments or the entire 
genome abolished the stimulatory capacity, suggesting these PAMP regions 
need to be liberated from the viral genome and antigenome to induce an antiviral 
response.  Indeed, when larger WNV RNAs were transfected into cells, RIG-I 
stimulation was detected over time, further supporting the hypothesis that 
PAMPs can be liberated by the host cell during the course of infection.  
Degradation of the WNV RNA via the host’s RNA processing pathways may be 
contributing to PAMP production, thus we began to examine methods of RNA 
degradation.  The endonuclease XRN1 has been previously shown to degrade 
WNV RNA and produce a discrete RNA fragment, the sfRNA.  When examined, 
the WNV sfRNA did not stimulate and RIG-I response.  This is not surprising, as 
other studies have concluded that the sfRNA serves to promote WNV 
neuroinvasiveness and thus serve as a pathogenicity factor (142, 164).  Mutation 
of the WNV 3’UTR such that the sfRNA is not produced reduces the lethality of 
the virus.  There is also data to suggest that the sfRNA may be acting as an 
inhibitor of RNAi, another cellular RNA degradation mechanism and important 
antiviral pathway, leading to an increase in virulence (159).  It remains possible 
that XRN1 may liberate other PAMPs during degradation of the viral genome, 
and examining knock down of XRN1 during WNV infection will provide 




Potential pathways involved in PAMP liberation 
Along with the XRN1, several other RNA degradation mechanisms have 
been defined that process viral RNAs.  The RNaseL pathway is an antiviral 
mechanism induced by viral RNA and is important in the liberation of RNA 
PAMPs over the course of HCV infection (109). 2’5’-linked oligoadenlyate 
synthase (OAS) responds to viral dsRNA PAMPs by producing 2’5’-linked 
oligoadenlytic acid, which serves to activate RNaseL, a ribonuclease that 
degrades RNA in the cell, including viral genomes (47).  Previous work has 
determined RNaseL is activated during WNV infection (156), therefore it would 
be of interest to examine the potential WNV PAMP producing capacity of this 
pathway.  However, OAS expression is IFN-dependent and requires an active 
antiviral response in order to initiate this particular RNA degradation mechanism. 
PAMPs recognized by RIG-I may result in the expression IFN and therefore lead 
to the activation the RNaseL pathway.  Therefore, the OAS, RNAse L pathway is 
likely to play a role in enhancing the antiviral response rather than serving to 
produce the initial PAMPs.  Therefore, the RNaseL pathway does not readily 
account for the induction of the initial antiviral response and the PAMPs 
recognized by RIG-I.   
The RNA interference (RNAi)/Dicer pathway is an evolutionarily conserved 
pathway in eukaryotes used to control gene expression by regulating RNA post-
transcriptionally.  The pathway utilizes small, interfering RNAs (siRNA) and micro 
RNAs (miRNA) for a variety of regulatory functions, including normal cellular 
gene expression, development and also as an antiviral control mechanism (186).  
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siRNAs are produced by the cleavage of exogenous, long, dsRNAs into small 
(~20nt), single stranded fragments by the cellular ribonuclease Dicer.  These 
siRNAs are then loaded into the RISC complex, which facilitates the base pairing 
of the siRNAs to corresponding regions of mRNA and inhibit translation.  The 
RNA is then degraded. miRNAs are host cell, non-coding RNAs that are similarly 
processed by Dicer, loaded into the RISC complex and then serve to regulate 
gene expression.  Viruses induce the RNAi pathway due to the prevalence of 
dsRNA species formed during the course of replication (63).  As a consequence, 
several viruses have evolved mechanisms to defend against the RNAi pathway.  
Many viruses encode viral proteins that function as suppressors of RNAi 
silencing (SRS), or have RNA regions that can serve in a similar SRS capacity 
(64, 172).  The sfRNA of WNV is proposed to serve as an SRS in both insect and 
mammalian cells.  Degradation of viral RNA by Dicer to form siRNA may, in 
addition to serving its function in the RNAi pathway, liberate potential PAMPs to 
be recognized by other PRRs in the host cell cytoplasm. If the Dicer pathway is 
important for PAMP production, the finding that the sfRNA interferes with it during 
the course of infection may also provide insight into how WNV is able to avoid 
detection by the host cell. 
Another potential mechanism involved in the formation of viral PAMPs is 
the adenosine deaminase that act on RNA (ADAR) proteins.  In mammals, there 
are three ADAR proteins, numbered 1, 2 and 3.  The ADARs act by deaminating 
adenosines found in dsRNA molecules to form inosine, a process referred to as 
hyper-editing.  This conversion can result in a destabilization of the RNA, as the 
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uridine base paired to the edited adenosine is not able to bind as readily to the 
converted inosine, resulting in degradation of the RNA molecule (125, 155).  
While the ADAR proteins normally act in cells in order to regulate gene 
expression, especially during development, they can also serve as antiviral 
proteins, given their specificity for dsRNA (153).  Of the ADAR family members, 
ADAR-1 is IFN inducible, implicating it as an antiviral effector molecule.  There is 
also evidence to suggest that hyper-editing by ADAR and the consequential 
destabilization of the RNA molecule can provide a target RNA for cleavage by 
Dicer, implicating ADAR-1 as a factor in the production of siRNAs and 
contributing to RNAi (154).  In the case of several paramyxoviruses, hyper-
editing by ADAR-1 reduces virulence in cells and results in less-infectious viral 
particles (193).  However, ADAR can also act in a pro-viral manner (62, 139, 
153).  During measles virus infection, hyper-editing of the matrix gene is found to 
be associated with a decrease in infectious particle production in CNS; however, 
these less infectious particles result in a persistent infection and can induce 
encephalitis, a serious neurological disease state (203).  Given the evidence for 
ADAR activity, both in an anti- and pro-viral capacity and it’s connection to the 
RNAi pathway, it is reasonable to investigate whether ADAR-1 editing in WNV 
infection may result in the production of RNAs able to serve as PAMPs identified 
by RIG-I. 
The final pathway for consideration during the initial investigation of the 
cellular RNA processing mechanisms that may contribute to PAMP production is 
the ER stress-induced inostiol-requiring enzyme-1 (IRE-1) pathway.  This 
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pathway is traditionally associated with degradation of proteins that are unfolded 
in the ER lumen as part of the unfolded protein response (UPR) (148, 184).  
Activated IRE-1 induces the cleavage of the mRNA xbp1, allowing it to be 
translated into an active X-box protein-1 (XBP-1) able to serve as a transcription 
factor for other stress induced proteins. The cytoplasmic domain of the IRE-1 
protein encodes the endoribonuclease responsible for this cleavage.  Other work 
has shown that in addition to the specific cleavage of xbp1, IRE-1 can cleave 
cellular mRNAs during stress responses (72, 73).  Infection of the cell induces 
membrane rearrangement, especially on the ER, to form platforms for viral 
replication, bringing IRE-1 into close association with the viral replication 
complex.  Indeed, WNV has been previously shown to modulate the IRE-1 
pathway, and several other viruses inhibit IRE-1 to avoid activation of the UPR, 
although there is no evidence connecting IRE-1 to viral RNA cleavage or 
processing (3, 138, 205, 212).  However, IRE-1 associated with these 
membranes can come into contact with viral RNAs and the domain of the protein 
that contains endoribonuclease function could potentially cleave viral genomic 
RNA, making it a potential contributor to RIG-I PAMP production. 
In the case of all of the RNA degradation pathways/mechanisms listed, an 
examination of the effect of knock down of these proteins/pathways on WNV 
replication and the kinetics of the antiviral response would help to illuminate their 
role in the production of RIG-I PAMPs.  Reduced activation of RIG-I pathway 
components, such as IRF-3, in knock down cells infected with WNV could 
indicate a failure to induce the RIG-I response.  Additionally, an increase in viral 
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replication and a delay in IFN production in knock down cells could be indicative 
of this pathway’s importance in the antiviral response to WNV.  Further analysis 
of pathways identified through initial knock down experiment would then serve to 
tease apart the specific proteins/steps within the pathway that are required for 
PAMP production and/or the induction of the RIG-I mediated antiviral response. 
Examination of PAMPs during a native infection 
Examination of RNAs pulled down along with RIG-I in the context of WNV 
infection would be the most direct way to identify PAMPs in vivo.  Analysis of 
RNA species bound to RIG-I in infection through RNAseq has been done with 
influenza A and SENV, revealing information concerning the structures required 
for RIG-I recognition of these viral PAMPs (12). Determining such basic 
characteristics, including size and structural features of the RNA, can help define 
the pathway responsible for PAMP production, further confirming studies 
examining RNA processing.  It would also provide general information regarding 
RNA PAMPs and the features required for RIG-I binding and activation, thus 
increasing our knowledge about this critical antiviral protein.  The development of 
antiviral therapies based on stimulating the RIG-I pathway during infection is a 
possible consequence of a greater understanding of the PAMPs required to 






Analysis of WNV PAMPs 
Differences in WNV PAMPs between strains may account for 
differential activation of the antiviral response 
 The work presented begins to define the structural characteristics 
required for a WNV RNA to serve as a RIG-I PAMP.  During the course of 
analyzing the WNV-NY 5’UTR, a comparison to the WNV-MAD78 5’UTR was 
made to examine the effects of a single base deletion from WNV-NY to WNV-
MAD78.  This revealed that the WNV-MAD78 5’UTR is a potent stimulator of the 
RIG-I response, consistently stimulating at the same level as the WNV-NY 
5’UTR.  However, preliminary analysis of the total viral genome suggests that 
there are differences in which regions can serve as PAMPs between the two 
viruses strains (Appendix 1).  Initial luciferase reporter assays suggest WNV-
MAD78 NS3 (+) stimulates RIG-I.  In contrast, WNV-MAD78 NS2a (+ and -), both 
of which stimulated in WNV-NY, do not appear to induce a RIG-I response.  The 
WNV-MAD78 RNAs stimulate as robustly as the identified WNV-NY PAMPs, 
indicating a strong RIG-I response to both WNV-NY and WNV-MAD78 PAMPs, 
when they are accessible.  Further analysis of the WNV-MAD78 genome for 
potential PAMP regions will fully define the regions capable of stimulating a RIG-I 
response.  Additionally, studies constructing chimeric viruses combining regions 





ssRNA and tertiary interactions may influence RIG-I stimulation 
The full length WNV-NY 5’UTR, WNV-MAD78 5’UTR and WNV-NY 1-90 
fragment were all capable of stimulating a robust RIG-I response, while the 
WNV-NY-SL stimulated to a lesser degree and WNV-NY 1-80nt fragment failed 
to stimulate RIG-I.  Structural analysis of the WNV-NY and WNV-MAD78 5’UTRs 
suggest regions of single stranded RNA present in these structures.  Such a 
region is suggested to be absent in the WNV-NY-SL and structural prediction of 
the WNV-NY 1-90 fragment also suggests this ssRNA region is absent.  
However, regions of ssRNA are not an absolute requirement for RIG-I activation 
as  constructs lacking single stranded regions still stimulatory.   However, all 
RNAs capable of inducing RIG-I are predicted to contain regions of tertiary 
interaction within the RNA.  Combined, the ssRNA region and the tertiary 
interaction may be required for optimal stimulation of RIG-I.  Indeed, one 
proposed mechanism of action for RIG-I is a “scanning model,” whereby RIG-I 
constantly scans cellular RNAs and is only activated once it contacts a specific 
PAMP (personal communication, Michael Gale).  RIG-I may be binding to the 
ssRNA regions of the 5’UTR initially while scanning, but is only activated once 
the protein encounters a region of dsRNA or a structure formed by tertiary 
interaction, denoting a viral PAMP.  Analysis of mutations producing ssRNA 
regions or disrupting tertiary interactions may further characterize the importance 
of these structural features for RIG-I stimulation.  Structural analysis of other 
identified PAMP regions of both WNV-NY and WNV-MAD78 will also provide 
information about the requirements of RIG-I/PAMP interaction, which will in 
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general provide useful information in the identification of viral PAMPs from other 
viral species.  It may also elucidate how viruses may circumvent the RIG-I 
response by altering or otherwise masking crucial structures required for proper 
binding to RIG-I during the course of infection. 
Steady state binding does not indicate RIG-I stimulatory capacity 
 We observed that steady-state binding of the 5’UTR RNA to RIG-I varies 
between species and that affinity does not correlate with stimulatory ability.  The 
WNV-NY and –MAD78 5’UTRs were both able to robustly stimulate RIG-I but 
both had much higher Kd values as compared to the 1-80nt fragment, which did 
not stimulate.  It is possible that the secondary structures within the RNA can 
also serve to bind multiple copies of RIG-I, which has been previously shown to 
occur, enhancing signaling of RIG-I through a multimerization effect and resulting 
in a more potent antiviral response overall (75, 87). Therefore, if the WNV-
MAD78 RNA has weaker binding affinity but is able to bind more RIG-I per 
molecule than WNV-NY RNA, inducing a stronger response, this may account for 
ability of the host to clear the WNV-MAD78 virus and prevent serious pathology 
as compared to WNV-NY.  Further examination of the binding of WNV RNAs and 
RIG-I through x-ray crystallography may serve to clarify these interactions. 
The role of DDX3 during WNV infection 
The DEAD/H helicase DDX3 has recently been characterized as playing a 
role in the RIG-I mediated antiviral response.  DDX3 has been suggested to 
serve as a sensor of viral RNA, interact with and activate RIG-I, or/and serve as 
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an activator of downstream signaling components such as IPS-1 and the 
TBK1/Ikkε complex (132, 162, 163).  DDX3 also plays a role in a variety of 
normal cellular processes involving RNA, such as export from the nucleus and as 
a part of the translation pre-initiation complex (33, 57, 68, 91, 167).  The work 
presented here suggests that DDX3 may co-localize with WNV proteins during 
infection, and infection results in the reduction of DDX3 protein levels at later 
time points.  However, there is no discernible difference in either viral replication 
or the antiviral response to WNV when DDX3 is overexpressed.  Co-localization 
studies and immunoprecipitation of DDX3 with RIG-I pathway members will help 
to illuminate the antiviral role of DDX3 during WNV infection.  Recent work has 
demonstrated that knock down of DDX3 negatively affects WNV replication, but 
the impact of knock down on the antiviral response to WNV has yet to be 
determined.  If DDX3 normally participates in the RIG-I mediated antiviral 
response but is prevented from functioning in this capacity, either by an active 
repression by WNV or because the virus is utilizing DDX3 for one of its other 
cellular roles, it could provide an attractive target for the development of antiviral 
therapies. 
It remains to be seen if the DDX3 protein, which has been implicated as a 
viral RNA sensor and as a component of the RIG-I mediated antiviral pathway, is 
active in this capacity during WNV infection.  Further work to fully characterize 
which regions of the WNV genome can stimulate RIG-I will need to be done to 
determine if differences in the PAMPs produced between strains are contributing 
to a differential activation of the RIG-I response.  The use of artificial ligands 
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designed based on information obtained by studying native ligands of RIG-I can 
be utilized for antiviral therapies.  These artificial RIG-I PAMPs help to increase 
the antiviral response and may result in a more rapid clearance of the virus.   
Studies testing such RIG-I ligands for use during HCV infection are ongoing 
(personal communication, Michael Gale).  Development of such broad-spectrum 
antiviral therapies would be beneficial for the treatment of numerous viral 
infections, including WNV. 
 The work presented here begins to analyze WNV PAMPs.  It is important 
to gain a proper understanding of how WNV is able to stimulate the antiviral 
response, how this response varies between strains, and to characterize the 
specific components required for the proper activation of the antiviral response.  
This information allows us to gain perspectives on treatment for infected 
individuals and to apply this knowledge more generally in analyzing infection with 
other viruses, again leading to more effective treatments during infection and 









Chapter 6 – Materials and Methods 
 
Cells and Viruses.  Huh7, Huh7.5 (Apath) and 293T (GeneHunter, 
Nashville TN) cells were propagated in Dulbelco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 1 mM non-essential amino acids and antibiotic/antimycotic solution 
(complete DMEM).  Sendai virus (SenV), Cantell strain was obtained from 
Charles River.  
 
Plasmids. pFL-WNV (166) was used as a template for PCR-amplification 
of the indicated segments of the WNV-NY genome (Table 1).  Primer sequences 
are listed in Appendix 2.   Amplified segments were cloned into pCAGGS, pVL-
blunt (a gift from Dr. Vincent Lee), pBluKSM or pWSK29 (a gift from Dr. Sydney 
Kushner, (189)  and the sequence confirmed.  The reporter plasmids pISG56-luc 
(a gift from Dr. Ganes Sens)(61) and pCMV-Renilla (Promega) encode the firefly 
luciferase gene under transcriptional control of the ISG56 promoter and the 
Renilla luciferase gene under the constitutively active cytomegalovirus (CMV) 
early promoter, respectively.  pEF-flag-N-RIG encodes the constitutively active 
N-terminus of RIG-I (208).  DDX3 was cloned into pEFBOS (117).  Construct 
produced are detailed in Appendix 3 and 4. 
Plasmid transfection.  Subconfluent monolayers of Huh7 cells in a 12-
well plate 200ng of pCAGGs construct encoding one gene of the WNV genome.  
	  
98	  
For DDX3 overexpression, subconfluent monolayers of 293T cells in a 6-well 
plate or BHK cells containing a WNV replicon (reference) in a 48-well plate were 
transfected with 500ng of pEFBOS-DDX3.  For IPS-1 cotransfection, 
subconfluent monolayers of Huh7 cells in a 48-well plate were transfected with 
200ng of pCDNA3.1-IPS-1 and 100, 200 or 300ng of pEFBOS-DDX3.  All 
transfections were done using Lipofectamine 2000 transfection reagent 
(Invitrogen). 
RNA fragments.  In vitro transcribed RNA fragments were generated 
according to the manufacturer’s protocol (Ampliscribe T3 and T7 kits; Epicentre).  
Briefly, a 20 µl reaction mixture containing 1 µg of linearized plasmid encoding 
the indicated RNAs was incubated at 42°C for 2 hr.  DNA template was 
subsequently removed from the reaction by treating with DNase I.  RNA was 
recovered by phenol/chloroform extraction followed by ethanol precipitation. 
Unless otherwise indicated, RNAs were treated with calf alkaline phosphatase 
(CIP) to remove free 5′ triphosphates (New England Biolabs).  The purity of the 
RNAs was confirmed by polyacrylamide gel electrophoresis.   The NS2b 
fragment was further purified on a 6% polyacrilamide gel containing 8 M urea.  
The RNA was eluted overnight at 4°C from the excised gel fragments in buffer 
containing 200mM NaCl, 10mM Tris-HCl pH 7.5, 1mM EDTA.  The eluted RNA 
was precipitated with ethanol, aliquoted and stored at -80oC.  The Amplicap kit 
(Epicentre) was used to generate the capped 5′ UTR segment and full length 
genomic RNA.  Monophosphorylated sub-genomic WNV RNA (sfRNA) was 
generated by incubating CIP-treated in vitro transcribed sfRNA with T4 
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polynucleotide kinase according to the manufacturer’s instructions (NEB).  WNV 
genomic RNA was isolated from culture supernatants recovered from WNV-NY 
infected cells.  Cell debris was removed by low speed centrifugation at 1500 rpm 
for 5 min and genomic RNA was recovered by Trizol  (Invitrogen) extraction. 
 Luciferase Reporter Assays.  Subconfluent monolayers of Huh7 or 
Huh7.5 cells in a 48 well plate were transfected with 100 ng of ISG56-luc and 20 
ng of pCMV-Renilla using Lipofectamine 2000 transfection reagent (Invitrogen).  
Where indicated, cells were also transfected with 200 ng of pEF-flagN-RIG or 
pCAGGs encoding a single WNV gene.  For protein expression experiments, 
cells lysates were prepared 24 hours post transfection.  For RNA transfections, at 
16 hr post-transfection, cells were mock-transfected, transfected with 500 ng or 2 
pmol of the indicated RNAs using TransMessenger transfection reagent 
(Qiagen), or infected with SenV (100 HA units), in triplicate.  Cell lysates were 
prepared 8 hr after RNA transfection or infection with SenV and luciferase levels 
were detected using a dual luciferase kit according to the manufacturer’s protocol 
(Promega).  Luciferase activity was quantified using a Berthold Centro XS3 
LB960 luminometer.  Normalized luciferase levels were determined by dividing 
firefly luciferase levels by control Renilla luciferase levels. Values represent the 
average luciferase expression compared to mock (± standard error) from a 
minimum of two independent experiments.  Statistical analysis was performed 
using Dunnett’s multiple comparison analysis. 
Trypsin Digestion.  Control dsRNA (Invivogen) or the indicated WNV 
RNA fragments (30 pmol) were incubated with purified E. coli-produced RIG-I (15 
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pmol) for 15 min at room temperature.  The RNA/RIG-I mixtures were digested 
with trypsin (0.83 mg) for 15 min at 37oC.  Trypsin was inactivated by the addition 
of protease inhibitor (Sigma) and the digestion products were separated on a 
12.5% SDS polyacrylamide gel.  Bands were visualized using Imperial Protein 
Stain (Thermo scientific). 
SHAPE analysis.  Selective 2’-hydroxyl acylation probed by primer 
extension was performed as previously described (115, 201).  Briefly, 2 pmol of 
RNA was incubated at 37°C in buffer (333 mM HEPES, pH 8.0, 333 mM NaCl, 
30 mM MgCl2) for 20 min.  RNA was then treated with either 60 mM 1M7 or 
DMSO for 10 min at 37°C.  RNA was ethanol precipitated and then used in 
primer extension with P32 radiolabeled primers using Superscript III reverse 
transcriptase (Invitrogen).  Sequencing reactions were also run concurrently with 
the DNA template used for in vitro transcription using the Thermosequenase 
cycle sequencing kit (USB). Extension products were separated on an 8% 
polyacrylamide 8M Urea gel and analyzed using a FLA-5100 phosphoimager.     
RIG-I binding.  Binding interactions were analyzed by Differential Radial 
Capillary Action of Ligand Assay (DRaCALA) as previously described (46, 147).  
Briefly, 1 nM P32 radiolabeled RNA was incubated with varying concentrations of 
E. coli purified RIG-I protein in binding buffer (100mM Tris, pH 7.5, 10mM NaCl) 
for 10 minutes.  Mixtures were then spotted onto dry nitrocellulose membrane 
and allowed to dry.  Results were imaged using a Kodak FLA-5000 
phosphoimager.  Quantification was done using the Multi Gauge software v3.0.  
Fraction Bound was calculated by measuring area and PSL intensity of the total 
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spot (Atotal and Itotal, respectively) and the area and PSL intensity of the inner 
spot (Ainner and Iinner, respectively) and utilizing the following equation: 
 
 Radiolabeled primers and RNA.  Primer used for primer extension 
(Appendix 2) and RNAs used for binding assays were labeled with γ-32P-ATP 
using T4 Polynucleotide Kinase at 30µCi/50pmol of RNA.  Unincorporated label 
was removed using an Illustra Microspin G-25 column (GE Healthcare). 
Immunofluorescence Assay.  Subconfluent Huh7 or 293T monolayers 
were grown on a microscope coverslip in a 35mm dish and then infected with 
WNV-NY at an MOI of 1.  At the indicated times post infection, cells were washed 
with 1x PBS and then fixed in 3% paraformaldehyde for 30 minutes.  Cells were 
permeabilized (0.2% TritonX-100, 1x PBS) and incubated at room temperature in 
blocking solution (1x PBS, 10% normal goat serum) for 1 hour.  Cells were 
incubated for 1 hour with polyclonal mouse-anti WNV (1:1000, Arbovirus 
Research Center, T35570) and a polyclonal rabbit-anti DDX3 (1:1000, Bethyl 
Labratories, A300-475A) in antibody diluent (1x PBS, 0.5% Tween-20, 3% bovine 
serum albumin).  Cells were then washed (1x PBS, 0.5% Tween-20) and 
incubated with goat anti-rabbit immunoglobulin G-Alexa 488 antibody conjugate 
(1:800, Molecular Probes) or goat anti mouse immunoglobulin G-rhodamine 
antibody conjugate (1:800, Jackson Immunoresearch).  Coverslips were inverted 
 Itotal - Iinner 




onto microscope slides and overlaid with Vectasheild solution (Vector Labs).  
Slides were visualized on an Olympus IX51 equipped with a digital camera. 
 Immunoblots.  293T cells were infected at an MOI of 1.  Cell were lysed 
in RIPA buffer (10 mM Tris pH 7.4, 150 mM NaCl, 0.02% NaN3, 1% sodium 
deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], and 1X 
protease inhibitors [Sigma]) at the indicated times post infection.  10-20 ug of 
total protein were separated by 10% SDS-polyacrylamide gel electrophoresis 
(PAGE) and transferred to a nitrocellulose membrane.  Membranes were blocked 
in blocking buffer (1x PBS, 5% milk, 0.1% Tween-20) and then incubated with 
primary antibodies to the following:  polyclonal rabbit-anti DDX3 (1:5000), 
polyclonal mouse-anti WNV (1:1000) or polyclonal rabbit-anti GAPDH (1:5000, 
Abcam, ab36845).  Goat anti rabbit and goat anti mouse secondary antibodies 
were peroxidase conjugated.  Blots were visualized using ECL Plus Western 
blotting detection reagents (Amersham Biosciences) followed by exposure to 
film.  
Virus Infection.  Subconfluent monolayers of 293T or Huh7 cells were 
washed once with DMEM and infected with WNV at a multiplicity of infection 
(MOI) of 1.  After 1 hour at 37°C, the inoculum was replaced with complete 
DMEM and cells were incubated at 37°C. Supernatants were collected at the 




 Plaque Assays.  Monolayers of Vero cells in a six-well plate were washed 
with DMEM followed by addition of serial dilutions of viral samples.  Cells were 
incubated in a 5% CO2 incubator for 1 hour at 37°C with rocking.  The inoculum 
was then removed and a 0.9% agarose-complete DMEM overlay was added.  
Cells were then incubated for 48 hours and a second overlay of agarose-DMEM 
containing 0.003% neutral red (MP Biochemicals) was applied. Plaques were 
















Appendix 1: Preliminary WNV-MAD78 PAMP data 
 
WNV-MAD78 is a strain of WNV isolated in Madagascar in 1978.  In mice, 
this strain is considered non-pathogenic, as it is does not result in neurological 
symptoms when injected at a peripheral site.  In contrast, infection with WNV-NY, 
a strain that has recently emerged in the western hemisphere, at peripheral sites 
can result in neurological symptoms and therefore, this strain is considered 
pathogenic (13).  Despite these differences in disease pathology, there is only a 
limited understanding of the factors that contribute to the differences in 
pathogenicity between strains.   
In order to compare the antiviral response between WNV-NY and WNV-
MAD78, the WNV-MAD78 genome is being examined for potential PAMPs.  RNA 
corresponding to the ten genes of the WNV-MAD78 genome were generated by 
in vitro transcribed and we are currently in the process of being tested for their 
stimulatory capacity. Preliminary data indicates that, as with the WNV-NY 
genome, several WNV-MAD78 RNAs are capable of inducing an antiviral 
response (Figure 32). NS3(+) appears to be stimulatory and E(+) may also 
stimulate, albeit weakly.  Conversely, regions that were stimulatory in WNV-NY, 
including NS2a(+) and NS2a(-), were not stimulatory from WNV-MAD78.   
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When experiments have been completed, a more definitive statement 
concerning the stimulatory capacity of these regions can be made.  However, the 
preliminary data suggests that different regions are capable of stimulating the 
innate immune response between the various strains of WNV.  Understanding 
the differences in PAMP regions between theses strains may help to clarify the 
RIG-I mediated response during infection, and help to elucidate if and how the 
innate antiviral response is a contributing factor to the differences in 
pathogenicity between strains. 
 
 
Figure 32: Stimulatory capacity of WNV-MAD78 RNA.  Huh7 monolayers were transfected 
with pISG56-luc and pCMV-Renilla 16 hr prior to infection with SenV or transfection with 500 ng 
of the indicated RNAs in triplicate.  Cell lysates were prepared 8 hr post transfection and assayed 



















































Appendix 2: Oligonucleotides 
 
Table 3: List of Oligonucleotides used for various experiments. 
Name Sequence 
PCR products   
    




WNV 97(as) CGAGATCTTCGTGCTAAGAAACAG 
T7 (sfRNA) 10504 (s) +Gs 
TAATACGACTCACTATAGGGAAGTCAGGCCG
GGAAG 
    
    
Site directed mutagenesis   
    
WNV-NY 5' knot #1 mutation 
TAATACGACTCACTATAGAGAATTTCTCGTTTG
AGACAAACTTAG 
    
Cloning   
WNV-NY   
    
WNV-NY 5'UTR s 
ATCGGCTAGCAGTAGTTCGCCTGTGTGAGCT
G 
WNV 5-UTR BamHI) as GATCGGATCCGAGATCTTCGTGCTAAGAA 
WNV-TX EcoRI-(C) s GGGAATTCGCCATGTCTAAGAAACCAGGAGG 
WNV-TX (C)-KpnI as CCGGTACCCCTCTTTTCTTTTGTTTTGAGC 
WNV-TX EcoRI-(prM) s GCGAATTCCATGAAAAGAGGAGGAAAGACCG 
WNV-TX (prM)-KpnI as ATGGTACCCCGCTGTAAGCTGGGGCCAC 
WNV-TX EcoRI-(E) s 
GCGAATTCATGAGCAACACCATGCAGAGAGTT
G 
WNV-TX (E)-KpnI as TTGGTACCCCAGCATGCACGTTCACGG 




WNV-TX (NS1)-KpnI as ACGGTACCCCAGCATTCACTTGTGACTGCA 
WNV-TX SacI-(NS2a) s CCGAGCTCATGTATAATGCTGATATGATTGA 
WNV-TX (NS2a)-KpnI as ATGGTACCCCGCGTTTACGGTTGG 
WNV-TX EcoRI-(NS2b) s AAGAATTCATGGGATGGCCCGCAACTG 
WNV-TX (NS2b)-KpnI as CCGGTACCCCTCTCTTTGTGTATTGGAGAG 
WNV-TX EcoRI-(NS3) s GAGAATTCATGGGAGGCGTGTTGTGGGACAC 
WNV-TX (NS3)-NsiI as ACCATGCATCCACGTTTTCCCGAGGCG 
WNV-TX EcoRI-(NS4a) s CCGAATTCATGTCTCAGATAGGGCTCATTGA 
WNV-TX (NS4a)-KpnI as ATGGTACCCCCTTCTCTGGCTCAGGAATTA 
WNV (NS4b) 7680a 
GCCTCTAGATCATCTTTTTAGTCCTGGTTTTTC
C 
WNV (NS4b) 7680a 
GCCTCTAGATCATCTTTTTAGTCCTGGTTTTTC
C 
WNV-NY NS5 (ClaI)s GATCATCGATATGGGTGGGGCAAAAGGACGC 
WNV-NY NS5 (smaI)a GCATCCCGGGCAGTACTGTGTCCTCAACC 
WNV-NY 3'UTR/NotI (s) ATCGGCGGCCGCTAGATATTTAATCAATTG 
WNV-NY 3'UTR as AACAATCTAGAGATCCTGTGTTCTCGCACCAC 
WNV-NY 
5'UTR+CS(BamHI195)as AAGGATCCAGCCCTCTTCAGTCCAATC 
WNV-NY E (XbaI-979)s AGTCTAGAGGAATGAGCAACAG 
WNV-NY 2b(EcoRV)s CCTCTAGAACTGAAGTGATGAC 
WNV-NY 2b(EcoRV)as TGGATATCTCTCTTTGTGTATTGG 
WNV-NY 4b(Xbal)s GGTCTAGAAACGAGATGGGTTG 
WNY-NY 4b(EcoRV)as CTGATATCTCTTTTTAGTCCTTTTTCC 
WNV-NY 5(EcoRV) AAGATATCGGTGGGGCAAAAGG 
WNV-NY 5(RV-10389)as ACGATATCTGTGTCCTCAACC 
T7 3'UTR (as) +Gs 
TAATACGACTCACTATAGGGAGATCCTGTGTT
CTCGCACCAC 
    
WNV-MAD78   
    
WNV-MAD EcoRI-(C) s GCGAATTCACCATGTCTAAGAAACCAGGAGG 
WNV-MAD (C)-KpnI as ACGGTACCCCTCTTTTCTTTTGTTTTGCGC 
WNV-MAD (anchC)-KpnI as ATGGTACCCCAGCGCCTGCGCAG 
WNV-MAD EcoRI-(prM) s GCGAATTCATGAAAAGAGGAGGTACAGCGG 
WNV-MAD (prM)-KpnI as ATGGTACCCCACTGTATGCCGGCGCTACTA 
WNV-MAD EcoRI-(E) s AAGAATTCATGAGCAACACGATGCAGCGAG 
WNV-MAD (E)-KpnI as TAGGTACCCCCGCATGGACGTTAACTGAGA 
WNV-MAD EcoRI-(NS1) s 
CCGAATTCATGATTGCTATGACGTTCCTTGCT
G 
WNV-MAD (NS1)-KpnI as AAGGTACCCCCGCATTCACTCTCGATTGCA 
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WNV-MAD SacI-(NS2a) s 
CCGAGCTCATGTACAATGCTGACATGATTGAT
CC 
WNV-MAD (NS2a)-KpnI as TTGGTACCCCCCGCTTGCGGTTAGGGT 
WNV-MAD EcoRI-(2b) s TTGAATTCATGGGATGGCCTGCTACAG 
WNV-MAD (NS2b)-KpnI as TTGGTACCCCACGTTTCGTGTATTGAAG 
WNV-MAD SacI-(NS3) s TTGAGCTCATGGGTGGTGTCTTGTGGGAC 
WNV-MAD (NS3)-KpnI as AAGGTACCCCGCGTTTCCCCGATGC 
WNV-MAD EcoRI-(NS4a) s GGGAATTCATGTCACAAATTGGGCTTGT 
WNV-MAD (NS4a)-KpnI as TTGGTACCCCCTTTTCAGGTTCTGGAATCA 
WNV-MAD (4b) sigseq fwd 
GCGAATTCACCATGCAGCGCTCACAGACTGAT
AAC 
WNV-MAD (4b) rev 
TACCATGCATCGTCTCTTCAGGCCAGGCTTCT
CC 
WNV-MAD EcoRI-(NS5) s AAGAATTCATGGGTGGGGCCAAAGGAC 
WNV-MAD (NS5)-KpnI as CCGGTACCCCCAAAACAGTGTCCTCTACAA 
    
DDX3   
    
hDDX3 (Nhe)s GGCTAGCTCAGGGATGAGTCATGTGG 














Appendix 3: Constructs used for protein expression 
 
Table 4: Contstructs used for protein expression experiments.  Nucleotide postions 
are based on the sequence from GenBank accession: a, AF404756; b, DQ176636; c, 
AF061337 
Construct Vector Restriction sites 
Position in the 
genome 
        
WNV-NYa       
pCAGGS-NY-C pCAGGs EcoRI/XmaI 98-465 
pCAGGS-NY-
prM pCAGGs EcoRI/XmaI 406-965 
pCAGGs-NY-E pCAGGs EcoRI/XmaI 904-2469 
pCAGGs-NY-
NS1 pCAGGs EcoRI/XmaI 2407-3525 
pCAGGs-NY-
NS2a pCAGGs KpnI/SacI 3525-4218 
pCAGGs-NY-
NS2b pCAGGs EcoRI/XmaI 4219-4611 
pCAGGs-NY-
NS3 pCAGGs EcoRI/XmaI 4612-6468 
pCAGGs-NY-
NS4a pCAGGs EcoRI/XmaI 6469-6915 
pCAGGs-NY-
NS4b pCAGGs EcoRI/XmaI 6916-7680 
pCAGGs-NY-
NS5 pCAGGs EcoRI/XmaI 7681-10395 
        
WNV-MAD78b       
pCAGGs-MAD-C pCAGGs KpnI/EcoRI 96-464 
pCAGGs-MAD-
prM pCAGGs KpnI/EcoRI 465-965 
pCAGGs-MAD-E pCAGGs KpnI/EcoRI 966-2468 





NS2a pCAGGs KpnI/SacI 3525-4217 
pCAGGs-MAD-
NS2b pCAGGs KpnI/EcoRI 4218-4610 
pCAGGs-MAD-
NS3 pCAGGs KpnI/SacI 4611-6467 
pCAGGs-MAD-
NS4a pCAGGs KpnI/EcoRI 6468-6913 
pCAGGs-MAD-
NS4b pCAGGs KpnI/EcoRI 6915-7682 
pCAGGs-MAD-
NS5 pCAGGs KpnI/EcoRI 7683-10397 
        
DDX3c       
















Appendix 4: Constructs used for in vitro transcription 
 
Table 5: Constructs used for in vitro transcription.  Nucleotide positions are 
based on the sequence from GenBank asscession numbers: a, AF404756; b, 
DQ176636 





WNV-NYa         
          
NY-5'UTR pBLuKSM KpnI/SacI WNV-NY 1-97 
NY-C pBLuKSM EcoRI/XmaI WNV-NY 98-465 
NY-prM pBLuKSM EcoRI/XmaI WNV-NY 406-965 
NY-E pBLuKSM EcoRI/XmaI WNV-NY 904-2469 
NY-NS1 pBLuKSM EcoRI/XmaI WNV-NY 2407-3525 
NY-NS2a pBLuKSM KpnI/SacI WNV-NY 3525-4218 
NY-NS2b pBLuKSM EcoRI/XmaI WNV-NY 4219-4611 
NY-NS3 pBLuKSM EcoRI/XmaI WNV-NY 4612-6468 
NY-NS4a pBLuKSM EcoRI/XmaI WNV-NY 6469-6915 
NY-NS4b pBLuKSM EcoRI/XmaI WNV-NY 6916-7680 
NY-NS5 pBLuKSM EcoRI/XmaI WNV-NY 7681-10395 
NY-3'UTR pBLuKSM XbaI/NotI WNV-NY 10396-11029 
NY-
5'UTR+CS pBLuKSM BamHI/SacI WNV-NY 1-196 
NY-
5'UTR+prM pBLuKSM KpnI/NotI WNV-NY 1-966 
NY-C-E pWSK29 XbaI/EcoRV WNV-NY 98-2467 
NY-E-NS2b pBLuKSM ClaI/XbaI WNV-NY 979-4102 
NY-NS2b-
NS4b pBLuKSM EcoRV/XbaI WNV-NY 4231-7679 
NY-NS4b-












          
WNV-
MAD78b         
          
MAD-C pBLuKSM KpnI/EcoRI 
WNV-
MAD78 96-464 
MAD -prM pBLuKSM KpnI/EcoRI 
WNV-
MAD78 465-965 
MAD-E pBLuKSM KpnI/EcoRI 
WNV-
MAD78 966-2468 
MAD-NS1 pBLuKSM KpnI/EcoRI 
WNV-
MAD78 2469-3524 
MAD-NS2a pBLuKSM KpnI/SacI 
WNV-
MAD78 3525-4217 
MAD-NS2b pBLuKSM KpnI/EcoRI 
WNV-
MAD78 4218-4610 
MAD-NS3 pBLuKSM KpnI/SacI 
WNV-
MAD78 4611-6467 
MAD-NS4a pBLuKSM KpnI/EcoRI 
WNV-
MAD78 6468-6913 
MAD-NS4b pBLuKSM KpnI/EcoRI 
WNV-
MAD78 6915-7682 
MAD-NS5 pBLuKSM KpnI/EcoRI 
WNV-
MAD78 7683-10397 
          
PCR products w/ T7 
promoter       
          
WNV-NY-
sfRNA N/A N/A WNV-NY 10504-11029 
WNV-
MAD78 
5'UTR N/A N/A 
WNV-
MAD78 1-96 
WNV-NY-SL N/A N/A WNV-NY 1-97 
WNV-NY 1-
90nt N/A N/A WNV-NY 1-90 
WNV-NY 1-
80nt N/A N/A WNV-NY 1-80 






Appendix 5: Structural predictions of WNV-NY PAMPs 
 
Figure 33: Strucutral predictions of the WNV-NY 5'UTR (+) and 3'UTR (-).  Structures 






























































































































































Figure 34 Strucutral predictions of the WNV-NY NS2a(+).  Structures produced with the sfold 
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Figure 35: Strucutral predictions of the WNV-NY E(-).  Structures produced with the sfold 
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Figure 36: Strucutral predictions of the WNV-NY NS2a(-).  Structures produced with the sfold 
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Figure 37 Strucutral predictions of the WNV-NY NS4a(-).  Structures produced with the sfold 











































































































































































































































Figure 38 Strucutral predictions of the full WNV-NY genome. Structures produced with the 
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Figure	  39 Strucutral predictions of the WNV-NY 5'UTR (+) alone, within the 5’-prM and within 
the full genome.  Structures of the WNV-NY 5’UTR alone (A), within the context of the 5’-prM 
RNA (B) or within the context of the full WNV-NY genome (C). Structures A & B were produced 
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